PO001

Hemophilia A use case scenarios for a portable testing device in Europe

A. M. Sijbers[1], T. Hamacher[2], M. G. van Lier[2], L. van Steinvoren – Stamsnijder[2], A. Bavinck[1,3,*], W. L. van Heerde[1,3]
[1]Enzyre BV, Nijmegen, [2]Holland Innovative, Eindhoven, [3]Department of Hematology, Radboudumc, Nijmegen, Netherlands

PO002

Extravascular distribution of factor IX: a pharmacological evaluation?

X. Delavenne[1,2], B. Guillet[3,4,*]
[1]Université de Lyon, INSERM, UMR 1059, Dysfonction Vasculaire et de l'Hémostase, [2]CHU de Saint-Etienne, Laboratoire de Pharmacologie – Toxicologie, Saint-Etienne, [3]University Hospital, Haemophilia Treatment Center, [4]Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France

PO003

Measurement and interferences of emicizumab up to six months after last infusion during laboratory follow-up in two cases of acquired haemophilia A

A. Launois[1], I. Martin-Toutain[2], F. Devaux[1], J. Lambert[3], T. Longval[3], F. Merabet[3], R. Jaidi[3], S. Le Doré[2], E. Ferré[2], P. Rousselot[3], E. de Raucourt[2], C. Flaujac[1,*]
[1]Laboratoire de biologie médicale, secteur hémostase, [2]Centre de ressources et compétences maladies hémorragiques, [3]Service d'Hématologie Clinique, Centre Hospitalier de Versailles, André Mignot, Le Chesnay - Rocquencourt, France

PO004

A single centre assessment of the frequency and clinical relevance of discrepant factor VIII assays both in persons without a disorder of haemostasis and in those with haemophilia A

J. A. Batac[1], M. Sutherby[2], S. Green[2], J. Sanders[2], D. Allsup[3,*]
[1]Haematology, Oxford University Hospitals, Oxford, [2]Haematology, Hull University Teaching Hospital Trust, [3]Hull York Medical School, University of Hull, Hull, United Kingdom

PO006

Clot waveform analysis in hemophilia A carriers

E. Drissi[1], F. Ben Lakhal[1], O. Ghali[1], W. El Borgi[1], S. Fekih Salem[1], K. zahra[1], L. Thabet[1], E. Gouider[1,*]
[1]Hematology, Aziza Othmana, tunis, Tunisia

PO007

FVIII inhibitors can be accurately determined in haemophilia A plasma in the presence of Mim8

K. Weldingh[1,*], W. Pickering[2], M. Robinson[2], C. Cogswell[2], M. Ezban[1]
[1]Novo Nordisk A/S, Bagsværd, Denmark, [2]Laboratory Corporation of America Holdings Englewood, Englewood, United States

PO008

Challenges in determining the severity of hemophilia A: an insight in discrepancies between factor VIII assays

M.-A. van Dievoet[1,*], I. Derclaye[1], S. Desmet[1], C. Gavard[1], C. Lambert[2], C. Hermans[2]
[1]Laboratory department, [2]Hematology department, Cliniques universitaires Saint-Luc, Brussels, Belgium

PO009

Laboratory monitoring of prolonged recombinant porcine FVIII treatment of 3 successive surgeries in the setting of acquired hemophilia

M. Daniel[1,*], E. Jeanpierre[1], M. Desvages[1], A. Dupont[1], S. Susen[1], A. Rauch[1]
[1]Hematology and Transfusion, Lille University Hospital, Lille, France

PO010

Synonymous variants in Hemophilia A and its clinical correlation: our experience at La Paz University Hospital

M. Fernández-Artazcoz[1,*], E. García-Pérez[1], R. Fernández Morata[2], F. Gómez Aguado[1,2], I. Rivas Pollmar[1], M. D. M. Gutiérrez Alvariño[1], M. Matín Salces[1], P. González-Marugán[1], M. G. Facal Giuliani[1], M. T. Álvarez Román[1], V. Jiménez-Yuste[1]

[1]Hematology, Hospital Universitario La Paz, [2]IDIPAZ. Instituto de investigación HU La Paz, Madrid, Spain

PO011

Blood viscoelastic testing could support the management of patients with hemophilia A

S. Hammer[1,2,*], M. Wekerle[1], M. Strauss[1], S. Kieninger[1], K. Althaus[1,2], T. Bakchoul[1,2]

[1]Center for Clinical Transfusion Medicine, [2]Institute for Clinical and Experimental Transfusion Medicine, Tuebingen, Germany

PO012

Stability of Eptacog Beta After Reconstitution

L. Burlot[1], N. Handké[1,*], Y. Marchi[2], F. Gautheron[2], G. Dettori-Campus[2]

[1]Biopharmaceutical Development Department, [2]Quality Manufacturing Department, LFB Biotechnologies, Les Ulis, France

PO013

Laboratory Markers of Bleeding in Hemophilia

L. Knowles[1,*], C. Wolter[1], M. Menger[1], M. Laschke[1], F. Hägele[1], H. Eichler[1], J. Pilch[1]

[1]Saarland University, Homburg, Germany

PO014

FVIII post infusion monitoring surveys: Results and analysis from the updated UK NEQAS BC Haemophilia programmes 2023.

A. Williams[1,*], C. Reilly-Stitt[1], S. Kitchen[1], I. Jennings[1], I. Walker[1]

[1]UK NEQAS BC, Sheffield, United Kingdom

PO015

Association of Thrombin activatable fibrinolysis inhibitor (TAFI) with the severity of haemophilia B

J. Pavić[1,*], M. Miloš[2,3], D. Coen Herak[2,4], G. Fressl Juroš[5], A. Boban[6,7], E. Bilić[7,8], S. Zupančić Šalek[9], R. Zadro[10]

[1]Department of Medical Biochemistry and Haematology Laboratory, General County Hospital Livno, Livno, Bosnia and Herzegovina, [2]Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia, [3]Faculty of Pharmacy, University of Mostar, Mostar, Bosnia and Herzegovina, [4]Faculty of Pharmacy and Biochemistry, University of Zagreb, [5]Department for Clinical-laboratory Diagnostics, Srebrnjak Children`s Hospital, [6]Department of Internal Medicine, University Hospital Centre Zagreb, [7]School of Medicine, University of Zagreb, [8]Department of Pediatrics, University Hospital Centre Zagreb, Zagreb, [9]Faculty of Medicine, University of Osijek, Osijek, [10]Medical Biochemistry Laboratory, St Catherine Specialty Hospital, Zagreb, Croatia

PO016

Comparison of clot-based and chromogenic assays for measurement of factor VIII inhibitors in hemophilia A patients

A. Jabri[1,*], M. Said[1], O. Ghali[1], F. Ben Lakhal[1], S. Fekih Salem[1], M. Riahi[1], Y. Nakhla[1], E. Gouider[1], W. El Borgi[1]

[1]Biological hematology department, Aziza Othmana hospital, Tunis, Tunisia

PO017

The thrombin generation assay as a method for monitoring hemophilia A patients using emicizumab and FVIII treatment

A. Monard[1,2,*], E. Urlings[3], T. van de Berg[2,4], D. Hellenbrand[3], R. van Oerle[2,5], E. Beckers[1,6], F. Heubel-Moenen[1], Y. Henskens[2,3]

[1]Internal Medicine - Hematology, Maastricht University Medical Centre+, [2]CARIM - school for cardiovascular disease, Maastricht University, [3]Central diagnostic laboratory, [4]Internal medicine , Maastricht University Medical Centre+, [5]Biochemistry, [6]GROW - school for oncology and reproduction, Maastricht University, Maastricht, Netherlands

PO018

Progression of Hemophilia treatment in developing countries compared to developed countries, advocating a need for increased collaboration measures: A Literature review

F. Dsouza[1,*]

[1]Research And Innovation, Childrens Health Ireland, Dublin, Ireland

PO019

IDENTIFICATION AND CHARACTERISATION OF A LARGE INSERTION RESPONSIBLE FOR SEVERE HAEMOPHILIA B

P. Bandini[1,2,3,*], N. Borràs[1,2], M. D. C. Gómez del Castillo Solano[4], M. F. López Fernández[4], M. Fernández Docampo[4], N. Comes[1,2], L. Ramírez[1,2], L. Martin-Fernandez[1,2], F. Vidal[1,2,5], I. Corrales[1,2,5]

[1]Laboratorio de Coagulopatías Congénitas, Banc de Sang i Teixits, [2]Medicina Transfusional, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona (VHIR-UAB), [3]Departament de Genètica, Microbiologia i Estadística, Universitat de Barcelona, Barcelona, [4]Servicio de Hematología, Complexo Hospitalario Universitario A Coruña, INIBIC, A Coruña, [5]Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Carlos III (ISCIII), Madrid, Spain

PO020

The possible role of OPG/RANKL system as biomarker in the progression of Hemophilic Arthropathy (HA)

S. Christidi[1,*], A. Kouramba[2], G. Thivaios[1], E. Kelaidis[2], T. M. Tryfou[3], M. -.-C. Kyrtsoni[3], O. Katsarou[2]

[1]Trauma and Orthopaedics Department, [2]Blood unit and National Reference Center for Congenital Bleeding Disorders, [3]First Department of Propaedeutic Internal Medicine, ''Laiko'' General Hospital, Athens, Greece

PO021

Investigation of the suitability of the ROTEM assay to measure coagulation potential in blood from patients on concizumab prophylaxis

H. Eichler[1,*], N. V. Butta[2], A. Riddell[3], C. Augustsson[4], M. Kjalke[5], A. P. Florencio[5], J. Astermark[6], V. Jiménez Yuste[2], P. Chowdary[3]

[1]Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg, Germany, [2]Department of Haematology, La Paz University Hospital-IdiPaz, Madrid, Spain, [3]KD Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom, [4]Department of Clinical Chemistry and Pharmacology, University and Regional Laboratories Region Skåne, Malmö, Sweden, [5]Novo Nordisk A/S, Søborg, Denmark, [6]Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden

PO022

Cross-reactivity of human anti-FVIII antibodies to porcine rFVIII: french field study to validate the modified Nijmegen method

V. Le Cam Duchez[1,*], C. Ternisien[2], E.-A. Guery[3], V. Eschwege[4], E. Jeanpierre[5], C. Nougier[6], V. Proulle[7], A. Stepanian [8], M. Tuffigo[9], R. Marlu[10], C. Pouplard[3]

[1]Hemostasis Laboratory, CHU Rouen , Rouen , [2]Hemostasis Laboratory, CHU Nantes, Nantes, [3]Hemostasis Laboratory, CHU Tours, Tours, [4]Hemostasis Laboratory, CHRU Nancy, Vandoeuvre Les Nancy, [5]Hemostasis Laboratory, CHRU Lille, Lille, [6]Hemostasis Laboratory, CHU Lyon, Bron, [7]Hemostasis Laboratory, Hopital Cochin, [8]Hemostasis Laboratory, Hopital

Lariboisiere, Paris, [9]Hemostasis Laboratory, CHU Angers, Angers, [10]Hemostasis Laboratory, CHU Grenoble, Grenoble, France

PO023

Evaluation of one-stage and chromogenic assays for the measurement of FVIII:C post valoctocogene roxaparvovec infusion

S. Platton[1,*], P. Raheja[1], C. Dale[2,3], S. Guy[4], N. Yartey[2,3], A. Bowyer[4]
[1]Royal London Hospital Haemophilia Centre, [2]Haemostasis Laboratory, Royal London Hospital, [3]National Health Service East and South East London Pathology Partnership, Barts Health NHS Trust, London, [4]Department of Coagulation, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

PO024

Investigating the role of factor VIII in endothelial cell function

C. Olgasi[1], A. Cucci[2], S. Assanelli[2], C. Sgromo[2], C. Borsotti[2], J. A. Giacchello[2], R. Santi[2], A. Follenzi[2,3,*]
[1]Department of Translational Medicine, [2]Department of Health Sciences, University of Piemonte Orientale, Novara, [3]Dipartimento Attività Integrate Ricerca Innovazione, Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, SSD Medicina Traslazionale, Alessandria, Italy

PO025

Expression of the Human Factor VIII Transgene from Dirloctocogene Samoparvovec, a Liver-Specific Recombinant Adeno-Associated Virus Gene Therapy, for up to 72 Weeks in Adult Mice

E. L. Blanchard[1,*], T. Antrilli[1], G. Jones[1], D. R. Peterson[1], G. Rivera-Pena[1], J. Silverberg[1], E. Heinzel[1], S. Smith[1], G. Atkins[1], J. Frick[1], C. Li[1], H. Beck[1], H. Hanby[1], J. M. Alexander[1], C. R. Riling[1]
[1]Spark Therapeutics, Inc., Philadelphia, United States

PO026

Sonorheometry for assessment of hemostatic status – results of preclinical verification.

M. Pikta[1,*], M. Ross[2], K. Rahuoja[2], I. Rätsep[3], R. Kruusat[3]
[1]Department of Laboratory Medicine, [2] Hematology Department, [3]Intensive Care Department, North Estonia Medical Centre, Tallinn, Estonia

PO027

Impact of differential binding of recombinant factor VIII concentrates to platelets on platelet functionality

A. Strebel[1,*], F. A. Pennacchio[1], S. Lickert[1], K. Selçuk[1], R. Klamroth[2], V. Vogel[1]
[1]Laboratory of Applied Mechanobiology, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland, [2]Zentrum für Hämophilie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany

PO028

Adults With Haemophilia B and History of Chronic HCV/HBV Infection Receiving Etranacogene Dezaparvovec Gene Therapy in the HOPE-B Clinical Trial Demonstrate Long-Term Bleeding Protection and Sustained FIX Activity 3 Years After Administration

A. von Drygalski[1,*], N. O'Connell[2], P. Verhamme[3], K. Meijer[4], P. van der Valk[5], R. Kazmi[6], P. Raheja[7,8], N. Galante[9], S. Le Quellec[9], R. Church[9], S. Lucas[9], G. Castaman[7], P. Monahan[9]
[1]Department of Medicine, Division of Hematology and Oncology, University of California San Diego, San Diego, United States, [2]National Coagulation Centre, St. James's Hospital, Dublin, Ireland, [3]Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Luven, Luven, Belgium, [4]Department of Haematology, University Medical Centre, University of Groningen, Groningen, [5]Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands, [6]University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom,

[7]Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy, [8]The Royal London Hospital, London, United Kingdom, [9]CSL Behring, King of Prussia, United States

PO029

Effect of Yoga on joint health in Person with Hemophilia

A. Dutta[1,*], B. J. Deka[2]
[1]Department of Medicine, Assam Medical College and Hospital , [2]Physiotherapy, Assam Medical College , Dibrugarh, India

PO030

Surgery in Hemophilia with Inhibitors under Emicizumab Prophylaxis

B. Zulfikar[1], G. Polat[2], B. Koc[1,*]
[1]Department of Pediatric Hematology/Oncology, Istanbul University Oncology Instıtute, [2]Department of Orthopedics and Traumatology, Istanbul University Istanbul Medical Faculty , Istanbul, Türkiye

PO031

Cardiovascular safety and brain protective effect of emicizumab in patients with hemophila older than 40

C. Hermans[1,*], E. Krumb[1], M.-A. Van Dievoet[2], C. Lambert[1]
[1]Hematology, [2]Biological Chemistry, Cliniques universitaires Saint-Luc, Brussels, Belgium

PO032

A Novel Gene Editing Lexicon Strategy for the Haemophilia Community

C. Hermans[1,*], C. D. Thornburg[2,3], C. Unzu[4], M. Kay[5], K. Starcevic[6], M. Pillai[6], M. Jones[7], M. Chiao[7], I. Antonino[8], C. Kessler[9]

[1]Saint-Luc University Hospital, Brussels, Belgium, [2]University of California San Diego, La Jolla California, [3]Rady Children's Hospital San Diego, San Diego, California, United States, [4]DNA&RNA Medicine Division. CIMA-Universidad de Navarra, IdisNA, Pamplona, Spain, [5]Stanford University, California, [6]Maslansky and Partners, New York City, New York, [7]Regeneron Pharmaceuticals, Inc., Tarrytown, New York, [8]Intellia Therapeutics, Inc., Cambridge, Massachusetts, [9]Georgetown University, Washington, District of Columbia, United States

PO033

Value of MRI in early detection and evaluation of hemophilic arthropathy; correlation with clinical evaluation

G. L. Khalifa[1,*], M. F. Amin[2]
[1]pediatric, [2]radiology, Minia University, Al Minya, Egypt

PO034

Interim results from a prospective, non-interventional study on the use of rVIII-SingleChain in patients with haemophilia A

J. Oldenburg[1,*], S. Juranek[2], O. Katsarou[3], S. Benchikh El Fegoun[4], I. Pabinger[5]
[1]Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, [2]Ludwig-Maximilians-Universität, Dr. von Haunersches Children Hospital, Munich, Germany, [3]National Reference Centre for Congenital Bleeding Disorders, Laiko Hospital, Blood Transfusion Centre, Athens, Greece, [4]CSL Behring, Bern, Switzerland, [5]Clinical Division of Haematology and Haemostaseology, Medical Clinic I, Medical University Vienna, Vienna, Austria

PO035

Validity and reliability of Thai version of the Paediatric Haemophilia Activities List (PedHAL)

R. Kongkasuwan[1,*] on behalf of Saran Simiwanich, M.D., Assoc. Prof. Bunchoo Pongtanakul, M.D., Pheeravut Tantisuvanitchkul, M.D., Suttirat Timdang, Wannika nuanta

[1]Rehabilitation Medicine, Siriraj hospital, Mahidol University, Bangkok, Thailand

PO036

A case of acquired factor XI deficiency and retroperitoneal bleed associated with Streptococcus pyogenes cellulitis

T. Szanto[1,*], N. El Beayni[1], M. Sivula[1], E. Poikonen[1], A.-E. Lehtinen[1], R. Lassila[1]
[1]Coagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

PO037

French real-word data on rIX-FP prophylaxis use in paediatric patients with haemophilia B

Y. Huguenin[1], A. Harroche[2], Y. Dargaud[3,4], A. Fournel[5], A. Rauch[6], C. Berger[7,8], F. Volot[9], B. Frotscher[10], C. Oudot-Challard[11], M. Pondrom[12], H. Catovic[13], C. Martin[13], A. Hassoun[14,*]
[1]HTC, Pellegrin Hospital, Bordeaux, [2]HTC, Dep. of Hematology, University Hospital Necker Enfants Malades, Paris, [3]Clinical Haemostasis Unit, National Reference Center of Haemophilia, Louis Pradel Hospital, [4]UR 4609 Haemostasis and Thrombosis, Claude Bernard University, Lyon, [5]HTC, University Hospital, Besançon, [6]HTC, National Reference Willebrand Centre, University Hospital, Lille, [7]HTC, University Hospital, Saint-Etienne, [8]INSERM, U 1059, Lyon University, Jean Monnet University, Sainbiose, [9]HTC Centre, Dijon Bourgogne University Hospital, Dijon, [10]HTC, University Hospital, Nancy, [11]University Hospital, HTC, Toulouse, [12]HTC, University Hospital, Nice, [13]CSL Behring, Paris, [14]HTC, Simone Veil Hospital, GH Eaubonne-Montmorency, France

PO038

Stable and durable factor IX levels over 4 years after etranacogene dezaparvovec gene therapy administration in a Phase 2b trial in patients with haemophilia B

A. von Drygalski[1,*], S. W. Pipe[2], A. Giermasz[3], E. Gomez[4], P. E. Monahan[5], S. Le Quellec[6]
[1]Hemophilia&Thrombosis Treatment Center, University of California , Division of Hematology/Oncology, San Diego, California, [2]University of Michigan, The Department of Pediatrics and Pathology, Ann Arbor, [3]University of California Davis, Division of Hematology/Oncology, Hemophilia Treatment Center , Sacramento, California, [4]Center for Inherited Blood Disorders, Orange County, California, [5]CSL Behring, King of Prussia, PA, United States, [6]CSL Behring, Hattersheim am Main, Germany

PO039

Real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Italy: HEM-POWR study subgroup analysis

A. Coppola[1,*], C. Santoro[2], M. N. D. Di Minno[3], G. Castaman[4], F. Peyvandi[5]
[1]Regional Reference Centre for Inherited Bleeding Disorders, University Hospital of Parma, Parma, [2]Hematology, University Hospital, Policlinico Umberto I, Rome, [3]Department of Translational Medical Sciences, Federico II University, Naples, [4]Careggi University Hospital, Florence, [5]IRCCS Maggiore Hospital, Milan, Italy

PO040

French real-word data on rIX-FP use for surgery in patients with haemophilia B

M. Fouassier[1], F. Volot[2], B. Tardy[3,4], A. Fournel[5], R. d'Oiron[6,7], C. Biron-Andreani[8], C. Reynes[9], Y. Huguenin[10], C. Berger[3,11], H. Catovic[12], C. Martin[12], B. Guillet[13,14,*]
[1]HTC, Hôtel-Dieu University Hospital, Nantes, [2]HTC Centre, Dijon Bourgogne University Hospital, Dijon, [3]HTC, University Hospital, [4]Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, [5]HTC, University Hospital, Besançon, [6]CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), Hôpital Bicêtre, AP-HP, Université Paris-Saclay, [7]Université Paris-Saclay, Le Kremlin Bicêtre, HITh, UMR_S1176, INSERM, Paris, [8]HTC, University Hospital, Montpellier, [9]University Hospital Annecy, HTC, Annecy , [10]HTC, Pellegrin Hospital, Bordeaux, [11]INSERM, U 1059, Lyon University, Jean Monnet University, Sainbiose,

[12]CSL Behring, Paris, [13]CHU Rennes, Inserm, EHESP, Irset - UMR_S 1085, Univ Rennes, F-35000 Rennes, [14]HTC, University Hospital, Rennes, France

PO041

Personalised prophylaxis with simoctocog alfa versus standard prophylaxis with efanesoctocog alfa in haemophilia A, a matching-adjusted indirect comparison

C. M. Kessler[1,*], F. F. Corrales-Medina[2], P. Mannuccio Mannucci[3], J. Astermark[4], M. D. Tarantino[5]
[1]Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, [2]Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Miami-Miller School of Medicine, and University of Miami-Hemophilia Treatment Center, Miami, United States, [3]Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center, Milan, Italy, [4]Department of Translational Medicine, Lund University, and Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden, [5]Bleeding and Clotting Disorders Institute, Illinois, United States

PO042

Personalised prophylaxis with simoctocog alfa versus standard emicizumab prophylaxis in haemophilia A, a matching-adjusted indirect comparison

C. M. Kessler[1,*], F. F. Corrales-Medina[2], P. Mannuccio Mannucci[3], J. Astermark[4], M. D. Tarantino[5]
[1]Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, [2]Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Miami-Miller School of Medicine, and University of Miami-Hemophilia Treatment Center, Miami, United States, [3]Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center, Milan, Italy, [4]Department of Translational Medicine, Lund University, and Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden, [5]Bleeding and Clotting Disorders Institute, Illinois, United States

PO043

Interim Analysis of Real-World Effectiveness and Usage of Recombinant Factor IX Fc for Surgical Haemostasis from the 24-Month Prospective, Non-Interventional B-MORE Study

H. Glosli[1], F. Peyvandi[2,3], D. Allsup[4,*], O. Katsarou[5], R. Berrueco[6], E. Bednar[7], S. Lauer[7], E. Gresko[8], E. Santagostino[8]
[1]Centre for Rare Disorders, Oslo University Hospital, Oslo, Norway, [2]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, [3]Università degli Studi di Milano, Department of Pathophysiology and Transplantation, and Fondazione Luigi Villa, Milan, Italy, [4]Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, United Kingdom, [5]Blood Transfusion Centre and National Reference Centre for Congenital Bleeding Disorders, Laiko General Hospital, Athens, Greece, [6]Pediatric Hematology Department, Sant Joan de Déu Hospital, Barcelona, Spain, [7]Sobi, Stockholm, Sweden, [8]Sobi, Basel, Switzerland

PO044

International Data Integration Program of the WFH World Bleeding Disorders Registry: bringing Europe data to the global stage

E. Ayoub[1], D. Coffin[1,*], C. Lambert[2], B. Konkle[3], C. Hermans[2], J. O'Hara[4], S. Diop[5], G. F. Pierce[1], E. Gouider[6], A. Iorio[7]
[1]World Federation of Hemophilia, Montreal, Canada, [2]Catholic University of Louvain, Leuven, Belgium, [3]University of Washington, Seattle, United States, [4]HCD Economics, Manchester, United Kingdom, [5]Cheikh Anta Diop University and Centre National de Transfusion Sanguine, Dakar, Senegal, [6]Hospital Aziza Othmana Tunis, Tunis, Tunisia, [7]McMaster University, Hamilton, Canada

PO045

Evaluation of Adherence to prophylaxis treatment in Hemophilia: are we achieving our goal?

D. M. D. C. Rocha[1], J. S. M. Duarte[1], A. Rocha Neto[1], M. D. P. S. V. Orletti[1], G. A. L. D. Santos [1], A. Liparizi[1], B. A. Calatrone[1], A. N. L. Prezotti[1,*]

[1]HEMOES, Vitoria, Brazil

PO046

CHALLENGES IN MANAGING MUCOSAL BLEEDING IN A PWH WITH HIGH TITRE OF INHIBITORS UNDER PROPHYLAXIS WITH EMICIZUMAB: A CASE REPORT

A. N. Totoianu[1,*], C. Marin[1], H. F. Vultur[2,3], A. Diaconu[1,4]
[1]Pediatric Department, Fundeni Clinical Institute, Bucharest, [2]Pediatric Department, Giurgiu County Emergency Hospital, Giurgiu, [3]PedMed.ro Network, [4]Pediatric Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

PO047

Treatment-related Humanistic Unmet Needs in Haemophilia B Without Inhibitors

A. Shapiro[1], C. Percier[2,*], T. Porstmann[2], J. R. Dusendang[3], A. P. Wheeler[4]
[1]Indiana Hemophilia and Thrombosis Center, Indianapolis, United States, [2]Novo Nordisk Health Care AG, Zurich, Switzerland, [3]PicnicHealth, San Francisco, [4]Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, United States

PO048

EMICIZUMAB IMPROVES THROMBIN GENERATION AND QUALITY OF LIFE COMPARED TO PREVIOUS FVIII PROPHYLAXIS IN HEMOPHILIA A PATIENTS

A. Marco-Rico[1,*], P. Marco-Vera[2]
[1]Hematology, University General Hospital Dr. Balmis, [2]Clinical Medicine Department, Miguel Hernández University, Alicante, Spain

PO049

Fragility fracture risk and bone mineral density predictive role in patients with hemophilia: a single center retrospective study

A. Giachi[1,*], R. Gualtierotti[1,2], P. Agosti[1], S. Marino[2,3], S. Scardo[3], S. Hassan[4], C. Suffritti[2], F. Peyvandi[1,2]
[1]Department of Pathophysiology and Transplantation, Università degli studi di Milano, [2]Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico di Milano, Centro Emofilia e Trombosi Angelo Bianchi Bonomi, S.C. Medicina – Emostasi e Trombosi, [3]Department of Biomedical Surgical and Dental Sciences, Università degli studi di Milano, Milan, Italy, [4]Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands

PO050

Clinical overview of perioperative outcomes from the XTEND-Kids study

A. Chan[1,*], S. Meunier[2], K. Fijnvandraat[3], M. T. Alvarez Roman[4], A. Kupesiz[5], J. Motwani[6], L. Malec[7,8], T. Wynn[9], A. L. Dunn[10], L.-S. Fetita[11], L. Abad-Franch[12], J. Dumont[13], L. Bystrická[14], B. Fuh[15]
[1]McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada, [2]Hospices Civils de Lyon, Groupement Hospitalier Universitaire Est, Unité Hémostase Clinique, Bron, France, [3]Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, Netherlands, [4]Rush University Medical Center, Rush Hemophilia and Thrombophilia Center, Chicago, IL, United States, [5]Akdeniz University, Antalya, Türkiye, [6]Department of Paediatric Haematology, Birmingham Children's Hospital, Birmingham, United Kingdom, [7]Versiti Blood Research Institute, [8]Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin, Milwaukee, WI, United States, [9]Division of Hematology and Oncology, Department of Pediatrics, University of Florida, Gainesville, FL, United States, [10]Division of Hematology/Oncology/BMT, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, OH, United States, [11]Sanofi, Paris, France, [12]Sobi, Basel, Switzerland, [13]Sanofi, Cambridge, MA, United States, [14]Sobi, Stockholm, Sweden, [15]Department of Pediatrics, East Carolina University, Greenville, NC, United States

PO051

A RARE CASE OF ACQUIRED HEMOPHILIA A IN A FEMALE

A. Surjit[1,*], B. J. Zachariah[2], D. Charles[3], J. Thomas[4]
[1]Aster Medcity, Kochi, India, [2]Internal Medicine, [3]Hematology, [4]Rheumatology, Aster Medcity, Kochi, India

PO052

REAL-WORLD DATA OF PROPHYLAXIS WITH EMICIZUMAB IN CHILDREN AND ADOLESCENTS WITH SEVERE HAEMOPHILIA: A SINGLE CENTRE EXPERIENCE

A. Michalopoulou[1], A. Dettoraki[1,*], H. Karelioti[1], S. Thymianou[1], N. Papageorgiou[1], I. Stamati[1], S. Saslis[1], Z. Kapsimali[1], H. Pergantou[1]
[1]Haemophilia Centre/Haemostasis and Thrombosis Unit, "Aghia Sophia" Children's Hospital, Athens, Greece

PO053

Paediatric Cases of Previously Untreated Patients with severe Haemophilia A and B on Extended Half Life Products : A Single Centre Experience

A. Dettoraki[1,*], A. Michalopoulou[1], N. Papageorgiou[1], S. Saslis[1], I. Stamati[1], S. Thymianou[1], Z. Kapsimali[1], H. Pergantou[1]
[1]Haemostasis and Thrombosis Unit, Haemophilia Centre, Aghia Sophia Children's Hospital, Athens, Greece

PO054

WOMEN DIAGNOSED WITH POSTPARTUM HEMOPHILIA, MORE THAN AN ANECDOTAL FACT: RETROSPECTIVE ANALYSIS IN A SINGLE CENTER.

B. L. Diaz Jordan[1,*]
[1]Hematology, Valdepenas General Hospital, Valdepenas, Spain

PO055

SATISFACTION WITH THE TREATMENT RECEIVED AND ADHERENCE IN HEMOPHILIC PATIENTS IN A RURAL AREA OF SPAIN.

B. L. Diaz Jordan[1,*]
[1]Hematology, Valdepenas General Hospital, Valdepenas, Spain

PO056

Pharmacoeconomy and clinical well-being in hemophilia (FARBENE): an interim analysis.

C. Sella[1,2,3,*], F. Valeri[1,2], C. Dainese[1,2], M. Bardetta[1,2,3], M. Scaldaferri[4], D. Cestino[4], F. Cattel[4], B. Bruno[2,3], A. Borchiellini[1,2]
[1]AOU Città della Salute e della Scienza, Regional Centre for Hemorragic and Thrombotic Disease, [2]AOU Città della Salute e della Scienza, Division of Hematology, [3]University of Turin, Department og Molecualr Biotechnology and Health Sciences, [4]Quality and Safety of Care, Hospital Pharmacy AOU Città della Salute e della Scienza, Turin, Italy

PO057

One-Stage Assay Analysis Demonstrates that Gene Therapy-Derived Factor VIII (FVIII) from Dirloctocogene Samoparvovec Reduced Clot Times Compared with Endogenous FVIII at Comparable FVIII Levels

C. Rizzo[1,*], I. Y. Rojas[1], E. L. Blanchard[1], D. Lupo[1], T. Chang[1], J. Coleman[1], V. Howard[1], L. Peed[1], R. Straub[1], H. Hanby[1], J. M. Alexander[1], C. R. Riling[1]
[1]Spark Therapeutics, Inc., Philadelphia, United States

PO058

One-stage bilateral hip arthroplasty in a patient with severe haemophilia B

C. E. Ursu[1,*], M. Serban[1], J. M. Patrascu[2], A. Traila[3], E. Boeriu[4], C. Jinca[4], I. Vaide [5], T. S. Arghirescu[4]
[1]Onco-Hematology Research Unit, Romanian Academy of Medical Sciences, Children Emergency Hospital "Louis Turcanu" Timisoara, European Hemophilia Treatment Centre, [2]Department of Orthopaedics, " Victor Babes " University

of Medicine and Pharmacy, Timisoara, [3]Medical Centre for Evaluation Therapy, Medical Education and Rehabilitation of Children and Young Adults, European Hemophilia Treatment Centre, Buzias, [4]Department of Pediatrics, Division of Onco-Hematology, " Victor Babes " University of Medicine and Pharmacy, Timisoara, Romania, [5]Institute of Clinical Medicine, University of Tartu, Tartu, Estonia

PO059

Hemophilia Surgery with Extended Half Life Products

D. A. Tuncel[1,*], D. A. Tuncel[1]
[1]pediatric hematology oncology, Adana City Hospital, Adana, Türkiye

PO060

The Rheumatologic Journey of Factor X Deficiency

D. Keskin[1,*], M. Direk[2] on behalf of reviewer
[1]Hematology, [2]Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye

PO061

Varna Expert center of coagulopathies and rare anemias – 10 years experience

E. Peteva[1,*] on behalf of Tomova G., Belcheva M., Kaleva V.
[1]Varna expert center of coagulation disorders and rare anemias, UNHAT ST MARINA, Varna, Bulgaria

PO062

Promoting Gender Equity in Hemophilia Care through Proactive and Systematic Screening of Hemophilia Carriers: Results of the PROCARRIERS1 study

E. Krumb[1,*], C. Lambert[1], A. Van Damme[1], C. Hermans[1]
[1]Division of Hematology, Hemostasis and Thrombosis Unit, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium

PO063

Unraveling Muscle Tension: A Study on Lower Extremity Muscle Stiffness in Hemophilia in Dependence of Joint Status.

F. Tomschi[1,*], M. Brühl[1], P. Ransmann[1], A. Schmidt[1], T. Hilberg[1]
[1]Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany

PO064

Surgical Procedures and Hemostatic Outcome in Patients with Hemophilia Receiving Concizumab Prophylaxis During the Phase 3 explorer7 and explorer8 Trials

F.-J. Lopez-Jaime[1,*], C. Barnes[2], A. K. C. Chan[3], S. Linari[4], T. Matsushita[5], J. Bovet[6], J. Odgaard-Jensen[6], L. H. Poulsen[7]
[1]Hospital Universitario Regional de Málaga, Málaga, Spain, [2]Royal Children's Hospital, Parkville, Australia, [3]McMaster Children's Hospital, McMaster University, Hamilton, Canada, [4]Center for Bleeding Disorders and Coagulation, Azienda Ospedaliero Universitaria Careggi, Florence, Italy, [5]Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, [6]Novo Nordisk, Søborg, [7]Department of Haematology, The Haemophilia Center, Aarhus University Hospital, Aarhus, Denmark

PO065

Hemophilia A with Low Activity of Factor VIII: A Case well managed with Homeopathy

G. Yaseen[1,*]
[1]Medicine, Saher Welfare Foundation, Lahore, Pakistan

PO066

Fc-fusion and glycopegylated rFVIII: pharmacokinetic comparison case series.

A. Poz[1], L. Contino[2], G. Barillari[1,*]
[1]University Hospital of Udine, Udine, [2]Azienda Ospedaliera "SS Antonio e Biagio", Alessandria, Italy

PO067

Novel insights into Factor VIII and FIX levels among pediatric hemophilia carriers

H. Fogarty[1,*], A. Busher[1], S. Ahmed[1], B. Nolan[1]
[1]Haemophilia Comprehensive Care Centre, Department of Haematology, Children's Health Ireland at Crumlin, Dublin, Ireland

PO068

Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Secondary Paediatric Analysis from the 24-Month French, Prospective, Non-Interventional B-SURE Study

H. Chambost[1,*], C. Oudot[2], F. Genre-Volot[3], B. Wibaut[4], C. Biron-Andreani[5], R. d'Oiron[6,7], S. Bayart[8], P. Chamouni[9], A. Harroche[10], S. Vanderbecken[11], M. Zidi[12], S. Lauer[13], H. Palmborg[13], E. Gresko[14]
[1]AP-HM, Department of Pediatric Hematology Oncology, Children Hospital La Timone & Aix Marseille University, INSERM, INRA, C2VN, Marseille, [2]Pediatric Oncology, CHU Limoges, Limoges, [3]Haemophilia Treatment Centre, University Hospital of Dijon, Dijon, [4]Haemophilia Treatment Centre, National Reference Willebrand Centre, University Hospital, Lille, [5]Haemophilia Treatment Centre, University Hospital of Montpellier, Montpellier, [6]CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), Bicêtre Hôpital, AP-HP, Paris-Saclay Université, Paris, [7]HITh, UMR_S1176, INSERM, Paris-Saclay Université, Le Kremlin-Bicêtre, [8]Centre Régional de Traitement de l'Hémophilie, CHU de Rennes, Bretagne, [9]Haemophilia Treatment Center, University Hospital of Rouen, Rouen, [10]Department of Hematology, Hospital Necker-Enfants Malades, GHU AP-HP, Centre - Université de Paris, Paris, [11]Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, [12]Sobi, Paris, France, [13]Sobi, Stockholm, Sweden, [14]Sobi, Basel, Switzerland

PO069

Registry of haemophilia carriers: A pilot study for the characterization of the joint health and the bleeding phenotype

F. J. López-Jaime[1], I. Fernández-Bello[1,*]
[1]Hospital Regional Universitario de Málaga, Málaga, Spain

PO070

Ultrasound for the assessment of arthropathy in patients with moderate hemophilia A: a multi-center cross-sectional study.

I. L. Calcaterra[1,*], F. Valeri[2], E. Baldacci[3,4], M. Napolitano[5], E. Zanon[6], G. Mazzucconi[7,8], C. Guerrino[1], S. Donnarumma[1], V. Palermo[1], E. Cimino[1], S. Siragusa[5], C. Martinoli[9], M. Di Minno[1]
[1]Federico II University, Naples, [2]Mollette Hospital, Turin, [3]Umberto I University Hospital, [4]La Sapienza University, rome, [5]University of Palermo, Palermo, [6]Padua University Hospital, Padua, [7]Ferrara University Hospital, [8]Ferrara University, Ferrara, [9]University of Genova, Genova, Italy

PO071

PROSPECTIVE ULTRASOUND ASSESSMENT OF THE JOINT STATUS IN 61 HEMOPHILIA PATIENTS IN A SINGLE PEDIATRIC CENTRE: 7-YEAR FOLLOW-UP RESULTS.

I. Ricca[1,*], B. Pollio[1], R. Albiani[1], C. Martinoli[2]
[1]SSD Medicina Trasfusionale Materno-Infantile e Traumatologica, AOU Città della Salute e della Scienza di Torino, Turin, [2]Dipartimento di scienze della salute - DISSAL, Università di Genova, Genoa, Italy

PO072

Joint status follow-up in haemophilia patients on prophylaxis with Efmoroctocog alfa using the haemophilia early arthropathy detection with ultrasound (HEAD-US) score: a single centre experience.

I. Ricca[1,*], B. Pollio[1], R. Albiani[1], C. Martinoli[2]
[1]SSD Medicina Trasfusionale Materno-Infantile e Traumatologica, AOU Città della Salute e della Scienza di Torino, Turin, [2]Dipartimento di scienze della salute - DISSAL, Università di Genova, Genoa, Italy

PO073

The costs and benefits of extended half-life clotting factors in patients with severe hemophilia A at a single institution

J.-Y. Hou[1,*], H.-C. Liu[1], T.-C. Yeh[1], T.-H. Huang[1], C.-Z. Lew[1], C.-Y. Cheng[1]
[1]Pediatric Hematology-Oncology, MacKay Children's Hospital, Taipei, Taiwan, Province of China

PO074

Joint health in participants with hemophilia A and hemophilia B without inhibitors treated with marstacimab from the phase 3 BASIS trial

J. Mahlangu[1,*], A. Palladino[2], E. Hwang[2], R. McDonald[3], C. Turich Taylor[3], J. Teeter[4]
[1]University of the Witwatersrand, Johannesburg, South Africa, [2]Pfizer Inc, Collegeville, PA, [3]Pfizer Inc, New York, NY, [4]Pfizer Inc, Groton, CT, United States

PO075

Epidemiological data and treatment strategies in haemophilia patients in a Portuguese Centre – differences between 2017 and 2023

C. Catarino[1], J. Felix[1,*], C. Câmara[1], C. Peixoto[1], F. Pires[1], A. Pereira[1], P. Afonso[2], F. Rodrigues[1]
[1]Imuno-hemoterapia, [2]Farmácia, Hospital de Santa Maria CHULN, Lisboa, Portugal

PO076

Artrial fibrillation - a challenge in patients with hemophilia A

K. Althaus[1,2,*], S. Hammer[1,2], J. Schreieck[3], T. Bakchoul[1,2]
[1]Institute for Clinical Transfusion Medicine, [2]Center for Clinical Transfusion Medicine, [3]Innere Medizin III, Department of Cardiology and Angiology, University Hospital Tuebingen, Tuebingen, Germany

PO077

Mental health outcomes from the Learning to Live with Non-severe Haemophilia study: First report using coreHEM Mental Health Outlook

K. Khair[1,*], S. Fletcher[1], M. Boyton[1], S. Bristow[1], M. Skinner[2,3], E. Clearfield[2], A. Kucher[4], M. Holland[1]
[1]Haemnet, London, United Kingdom, [2]IPA Ltd, Washington, United States, [3]McMaster University, Montreal, Canada, [4]Patient Outcomes Research Group (PORG), Washington, United States

PO078

First report of lived experience from the Learning to Live with Non-Severe Haemophilia study.

K. Khair[1,*], S. Fletcher[1], M. Holland[1]
[1]Haemnet, London, United Kingdom

PO079

Patient preferences and usage patterns of mobile device applications for haemophilia A prophylaxis in Eastern Europe: results from a descriptive, observational, cross-sectional, survey-based study

L. Nemes[1,*], H. Hartmann[2], H. Kostalec[3], T. Roblek[4]
[1]National Haemophilia Center and Haemostasis Department, Center Hospital of Northern Pest – Military Hospital, [2]Takeda Pharma Kft., Budapest, Hungary, [3]Takeda Pharmaceuticals Croatia d.o.o., Zagreb, Croatia, [4]Takeda Pharmaceuticals farmacevtska družba d.o.o., Ljubljana, Slovenia

PO080

Combined Haemophilia A and C: a case report

L. Fonseca[1,*], L. Moura[1], A. Brito[1], F. Lobo[1], M. Costa[1]
[1]Centro Hospitalar Tondela-Viseu, Viseu, Portugal

PO081

Zero bleeds followed the administration of albutrepenonacog alfa, the rIX-FP with fewer frequency of administration in an Argentinian cohort.

J. Schmiedl[1] on behalf of María Sol Cruz, Sandra Borchichi, Susana Gastaldo, María Elena Sánchez, Gabriela Sciucatti, Andrea Torressi, Patricia Casais, L. Aversa[2,*], D. Neme[3] on behalf of received research grants, honoraria for speaker activities, AB, participation in CT from CSL Behring, Novo Nordisk, Roche, Sanofi, Takeda
[1]Medical, CSL Behring, Bern, Switzerland, [2]Medical, CSL Behring, [3]Directora Medica, Fondacion De La Hemophila, Buenos Aires, Argentina

PO082

Emerging and exciting new treatments in hemophilia future

L. M. Moura[1,*], L. Fonseca[1], E. Rodrigues [1], R. F. Lobo[1], A. Brito[1], M. Costa[1]
[1]Imunohemotherapy , Centro Hospitalar Tondela- Viseu, Viseu , Portugal

PO083

PROPHYLAXIS IN PATIENTS WITH MODERATE-MILD FORMS OF HEMOPHILIA:EXPERIENCE IN A SINGLE CENTER

M. Lopez[1,*], R. I. Varela[1], E. L. Ansoar[1], O. D. Muñiz[1], C. A. Lopez[1]
[1]Haematology, Alvaro Cunqueiro Hospital, Vigo, Spain

PO084

ILIAC STENT IN MILD HA AND ARTERIAL PERIPHERAL DISEASE: EXPERIENCE FROM A SINGLE CENTER

M. Lopez[1,*], R. I. Varela[1], E. L. Ansoar[1], O. D. Muñiz[1], C. A. Lopez[1]
[1]Haematology, Alvaro Cunqueiro Hospital, Vigo, Spain

PO085

Real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by age groups: Pooled analysis (A-SURE/PREVENT)

M. T. Álvarez Román[1,*], J. Oldenburg[2], C. Escuriola Ettingshausen[3], S. Lauer[4], M. Fusser[4], E. Gresko[5], S. Lethagen[4,6]
[1]Department of Haemotology, La Paz University Hospital-IdiPaz, Madrid, Spain, [2]University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, [3]HZRM Hemophilia Center Rhine-Main, Mörfelden-Walldorf, Germany, [4]Sobi, Stockholm, Sweden, [5]Sobi (former employee), Basel, Switzerland, [6]Copenhagen University, Copenhagen, Denmark

PO086

Bleeding and Clotting Paradox: A Child with Hemophilia B and cTTP Encounters Anaphylaxis Post-ITI and Triumphs with the Beutel Protocol

M. Hetman[1,*], E. Latos-Grazynska[1]
[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Clinical Hospital, Wroclaw, Poland

PO087

The Hemophilia B Divergent Path: When Eggs Deceive and Diverticula Reveal

M. Hetman[1,*], E. Latos-Grazynska[1]

[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Clinical Hospital, Wroclaw, Poland

PO088

Trial in Progress: Disease Characteristics of Hemophilia B in Patients Receiving Standard-of-Care Prophylactic Factor IX (FIX) Replacement Therapy

M. P. O'Brien[1,*], S. W. Pipe[2], G. F. Pierce[3], L. Sabin[1], D. Chalothorn[1], K.-C. Chan[1], K. Tuckwell[1], K. Deshmukh[1], R. Reinhardt[4], A. Haagensen[4], L. Walsh[4], D. E. Gutstein[1]
[1]Regeneron Pharmaceuticals, Inc., Tarrytown, NY, [2]Departments of Pediatrics and Pathology, University of Michigan Medical School, Ann Arbor, MI, [3]Independent Consultant, La Jolla, CA, [4]Intellia Therapeutics, Inc., Cambridge, MA, United States

PO089

Skeletal Complications in Patients with Hemophilia

M. Bordbar[1,*]
[1]Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic Of

PO090

Emicizumab as a primary and immediate standalone therapy for acquired hemophilia A: shaping a novel therapeutic approach for a complex hematological condition

M. Thiry[1,*], C. Lambert[1], M.-A. Van Dievoet[2], C. Hermans[1]
[1]Hematology, [2]Biological Chemistry, Cliniques universitaires Saint-Luc, Brussels, Belgium

PO091

OUTCOMES OF EMICIZUMAB–kxwh USE IN PERSONS WITH HEMOPHILIA A AT MOI TEACHING AND REFERRAL HOSPITAL

M. E. Oburah[1,2,*], F. Njuguna[1,3], A. Greist[1,4], C. Kilach[1], R. .. Ramani[5], K. .. Ndemo[6], C. Njuguna[1], E. Aliwa[1]
[1]Hematology & Oncology, Academic Model Providing Access to Healthcare (AMPATH)_ MTRH, Eldoret, [2] School of Pharmacy, Mount Kenya University, Nairobi, [3]School of Medicine, Moi University, Eldoret, Kenya, [4]Hematology and other bleeding disorders, Indiana Hemophilia and Thrombosis Centre_ (IHTC), Indiana, United States, [5] School of Pharmacy, Pharmaceutical Chemistry, [6] School of Pharmacy, Clinical Pharmacy, Mount Kenya University, Nairobi, Kenya

PO092

Future of Hemophilia Patient Registries: A Pioneering Initiative in the UAE

H. Al Rufaye[1], A. Khanani[1], I. Khanani[1], K. Al Habayba[1], H. Osman[2], H. Musa[3], M. Abd El Fattah[4], M. F. Khanani [1,*]
[1]Pediatric Hematology Oncology, [2]Adult Hematology Department, Tawam Hospital, Al Ain, United Arab Emirates, [3]Accsight LLC, Cairo, Egypt, [4]Accsight, Jeddah, Saudi Arabia

PO093

Circumcision in patients with hemophilia: using the classic reduced dose regimen of factor concentrates.

N. Guerd[1], H. Belhadef[1], H. Bezzou[1], I. Chekkaf[1], F. Bendahmene[1], N. Mesli[1,*]
[1]MEDICINE, CHUT, TLEMCEN, Algeria

PO094

Safety, efficacy, and laboratory profile of reduced Emicizumab dosing in hemophilia A patients

N. El Beayni[1,*], T. Szanto[1], A. E. Lehtinen[1], R. Lassila[1]
[1]Helsinki University Hospital, Helsinki, Finland

PO096

Observational, PRO study to Evaluate Quality of Life for Hemophilia patients on Hemlibra, Single study

O. F. Kashari[1,*], S. A. Babakr[1], A. M. Alqaisi[1]
[1]Hematology Department, Al Aziziyah Children Hospital, Jeddah, Saudi Arabia

PO097

Using of Emicizumab in Pediatric Hemophilia a Patients: KSA Single Center Experience

O. Kashari[1,*], A. A. Tayeb[2], E. A. Baothman[1], A. M. Alqaisi[1]
[1]Hematology, Al Aziziyah Children Hospital, [2]Pediatric, East Jeddah hospital, Jeddah , Saudi Arabia

PO098

A case of thrombosis in a patient with severe hemophilia B

O. Yastrubinetskaya[1,*], N. Zozulia[1], E. Yakovleva[1]
[1]National Medical Research Center for Hematology, Moscow, Russian Federation

PO099

Real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by disease severity: Pooled analysis (A-SURE/PREVENT)

P. A. Holme[1,*], M. T. Álvarez Román[2], A. Tagliaferri[3], J. Oldenburg[4], S. Halimeh[5], S. Lauer[6], M. Fusser[6], E. Gresko[7], S. Lethagen[6,8]
[1]Department of Haematology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, [2]Department of Haematology, La Paz University Hospital-IdiPaz, Madrid, Spain, [3]Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Parma, Italy, [4]University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, [5]Gerinnungszentrum Rhein Ruhr, Duisburg, Germany, [6]Sobi, Stockholm, Sweden, [7]Sobi (former employee), Basel, Switzerland, [8]Copenhagen University, Copenhagen, Denmark

PO100

The value-based healthcare approach to haemophilia: development of outcome measures for the evaluation of care of people with haemophilia.

P. A. Cortesi[1,*], C. Fornari[1], S. Conti[1], B. Pollio[2], E. Boccalandro[3], A. Buzzi[4], C. Carulli[5], A. Coppola[6], R. De Cristofaro[7], M. N. D. Di Minno[8], G. Dolan[9], E. Ferri Grazzi[10], A. Fornari[1], R. Gualtierotti[3], C. Hermans[11], V. Jiménez- Yuste[12], G. Kenet[13,14], A. Lupi[10], C. Martinoli[15,16], M. F. Mansueto[17], G. Nicolò[18], A. Tagliaferri[6], A. Gringeri[19,20], A. C. Molinari[21], L. G. Mantovani[19,22,23], G. Castaman[24] on behalf of V.B.H.2 project group
[1]Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, [2]Transfusion Medicine, "Regina Margherita" Children Hospital, Regional Reference Centre for Inherited Bleeding and Thrombotic Disorders, Turin, [3]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center,, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [4]Fondazione Paracelso, Milan, [5]Orthopaedic Clinic, University of Florence, Florence, [6]Regional Reference Centre for Inherited Bleeding Disorders, University Hospital of Parma, Parma, [7]Haemorrhagic and Thrombotic Disease Service, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, [8]Department of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II University, Naples, Italy, [9]Guys' and St Thomas' NHS Trust, London, United Kingdom, [10]Federation of Haemophilia Associations (FedEmo), Milan, Italy, [11]Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussel, Belgium, [12]Thrombosis and Haemostasis Unit - IdiPAZ, University Hospital La Paz, Madrid, Spain, [13]National Hemophilia Center, Thrombosis Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, [14]Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, [15]Department of Health Science - DISSAL, University of Genoa, [16]IRCCS Ospedale Policlinico San Martino, Genoa, [17]Division of Hematology, University Hospital Paolo Giaccone, Palermo, [18]Department of Healthcare Professions,, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [19]CHARTA Foundation, Milan, [20]Solidarity Health Care Center, Lucca, [21]Regional Reference Centre for Haemorrhagic Diseases, IRCCS Istituto Giannina Gaslini, Genoa, [22]Research Centre on Public Health (CESP),

University of Milan-Bicocca, [23]Istituto Auxologico Italiano, IRCSS, Milan, [24]Department of Oncology, Centre for Bleeding Disorders and Coagulation,, Careggi University Hospital, Florence, Italy

PO101

FOLLOW-UP OF HEMOPHILES AND MANAGEMENT OF COMPLICATIONS

R. Ben Sghaier[1,*], A. Guizani[1], M. guermazi[1], M. zaier[1], W. chenbah[1], W. bouteraa[1], K. zahra[1], H. regaieg[1], Y. ben youssef[1], N. ben sayed[1], A. khelif[1]
[1]Hematology Department, Farhat Hached University Hospital Sousse, sousse, Tunisia

PO102

Particularities of care for hemophilic children

R. Ben Sghaier[1,*], F. cherif[1], M. guermazi[1], M. zaier[1], K. zahra[1], W. bouteraa[1], W. chenbah[1], N. ben sayed[1], Y. ben youssef[1], H. regaieg[1], A. khelif[1]
[1]Hematology Department, Farhat Hached University Hospital , Sousse, Tunisia

PO103

Immune Tolerance Induction with a Recombinant Factor VIII Fc in Haemophilia A: Final Data from a Chart Review Study

R. Klamroth[1,*], M. A. Saleh[2], H. Glosli[3], M. Schiavulli[4], B. Guillet[5], L. Bystrická[6], A. Schönstein[7], S. Lethagen[6,8]
[1]Vivantes Klinikum Friedrichshain, Berlin, Germany, [2]King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, [3]Centre for Rare Disorders, Oslo University Hospital, Oslo, Norway, [4]Haemophilia and Congenital Bleeding Disorders, Treatment Center Santobono-Pausilipon Children Hospital, AORN, Naples, Italy, [5]Centre for Bleeding Disorders, Rennes University Hospital, Inserm U1085, Rennes, France, [6]Sobi, Stockholm, Sweden, [7]Veramed, Frankfurt am Main, Germany, [8]Copenhagen University, Copenhagen, Denmark

PO104

Insights from people with haemophilia in France: Patient perspectives on the concizumab pen-device

S.-M. Castet[1,*], N. Béranger[2], L. Sepot-Boucherit[2]
[1]HTC, Bordeaux-GH Pellegrin University Hospital, Bordeaux, [2]Rare Disease, Novo Nordisk, Paris, France

PO105

Surgeries in haemophilia patients: An experience of tertiary care hospital in Northern India

S. Wadhera[1,*], A. Jain[1], J. Ahluwalia[2], N. Kumar[2], K. SR[3], A. Savlania[4], P. Malhotra[1]
[1]Department of Clinical Hematology and Medical Oncology, [2]Department of Hematology, [3]Department of Orthopedics, [4]Department of General Surgery, PGIMER, Chandigarh, India

PO106

Joint health in patients with hemophilia: data from real-life practice in Colombia

F. Yepes[1], S. Parra[2], C. Becerra-Arias[3], C. Sossa[3], S. Prasca[1,*], J. Donado[1], N. Duque-Zapata[1]
[1]Medicarte, Medellin, [2]Medicarte, Pereira, [3]Medicarte, Bucaramanga, Colombia

PO107

Enhancing haemophilia assessment and monitoring with novel digital biomarkers

S. Lobet [1,2,*], A. Lebreton[3], A. Plaud[4], A. Feyt[4], C. Gorin[4], L. Carment[4], E. Guilpain[4], A. Petitmangin[4], S. Zinaï[4], L. Frenzel[5,6], C. Négrier[7]
[1]Haemostasis and Thrombosis Unit, Division of Hematology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), [2]Neuromusculoskeletal Lab (NMSK), Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain (UCLouvain), Brussels, Belgium, [3]Service d'hématologie biologique, CHU Clermont-Ferrand, Clermont-Ferrand, [4]Ad Scientiam, [5]Department of Haematology, Necker-Enfants

Malades Hospital (AP-HP5), Paris-Centre University, [6]INSERM U1163, Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, Imagine Institute, French National Reference Center for Mastocytosis (CEREMAST) , Paris, [7]UR4609 Hémostase & Thrombose, Université Lyon 1, Faculté de Médecine Lyon Est, Lyon, France

PO108

ACTIVLIM-Hemo, a new valid, reliable, unidimensional and linear measure of activity limitations in hemophilia

S. Lobet[1,2,3,*], C. Hermans[1], C. Lambert[1], M. Penta[4,5]
[1]Haemostasis and Thrombosis Unit, Division of Hematology, Clinique universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), [2]Service d'ergothérapie et de kinésithérapie, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), [3]Neuromusculoskeletal Lab (NMSK), Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain (UCLouvain), Brussels, [4]Institute of Neuroscience, Université catholique de Louvain (UCLouvain), Louvain-la-Neuve, [5]Arsalis SRL, Glabais, Belgium

PO109

The VINCEREMO pilot study: physical activity and prophylaxis in hemophilia: How, When and Why. Final results.

S. Carola[1,2,3,*], V. Federica[1,2], D. Cristina[1,2], M. Piera[4], B. Benedetto[2,3], B. Alessandra[1,2]
[1]Regional Centre for Hemorrhagic and Thrombotic Diseases, [2]Division of Hematology, AOU Città della Salute e della Scienza, [3]Department of Molecular Biotechnology and Health Sciences, University of Turin, [4] Orthopedics and Traumatology Departement, AOU Città della Salute e della Scienza, Turin, Italy

PO110

FREQUENCY OF ULTRASOUND (US) FOR JOINT EVALUATION IN HEMOPHILIA: THE MONTREAL STUDY

S. Carola[1,2,3,*], V. Federica[1,2], D. Cristina[1,2], B. Benedetto[2,3], B. Alessandra[1,2]
[1]Regional Centre for Hemorrhagic and Thrombotic Diseases, [2]Division of Hematology, AOU Città della Salute e della Scienza, [3]Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy

PO111

Achieving Zero Annual Bleed Rate with Tailored Prophylaxis in Low and Middle Income countries : A retrospective observational study

S. Francis[1,2,*], V. N. Pillai[1], N. Sidharth[2], S. George Chiramal[1], L. Paul[1]
[1]HTC, Aluva, [2]Clinical Hematology, Amritha Institue of Medical Sciences, Cochin, India

PO112

CLINICAL AND ECONOMIC IMPACT OF SWITCHING A STANDARD TO AN EXTENDED FACTOR VIII IN A GROUP OF HAEMOPHILA A PATIENTS – THE EXPERIENCE OF A PORTUGUESE CENTRE

C. Catarino[1], S. Ferreira[2,*], C. Rey[3], E. Cardoso[3], E. Rocha[4], A. Pereira[1], P. Afonso[5], F. Rodrigues[1]
[1]Centro de Referência de Coagulopatias Congénitas - Centro Hospitalar Universitário Lisboa Norte - Hospital Santa Maria, Lisboa, [2]Serviço de Imunohemoterapia - Centro Hospitalar Barreiro Montijo, Barreiro, [3]Serviço de Imunohemoterapia - Centro Hospitalar Universitário do Algarve - Hospital de Portimão, Portimão, [4]Serviço de Pediatria - Centro Hospitalar Universitário do Algarve - Hospital de Faro, Faro, [5]Serviços Farmacêuticos - Centro Hospitalar Universitário Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal

PO113

Efanesoctocog Alfa Prophylaxis Outcomes in European Patients From the XTEND-1 Trial

S. Susen[1,*], J. Oldenburg[2], C. Königs[3], F. Peyvandi[4], U. Khan[5], L. Bystrická[6], E. Santagostino[7], L. Abad-Franch[7], P. Chowdary[8]
[1]Institut d'Hématologie-Transfusion, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France, [2]Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, [3]Goethe University, University Hospital Frankfurt, Department of Paediatrics and Adolescent Medicine, Clinical

and Molecular Haemostasis, Frankfurt, Germany, [4]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [5]Sanofi, Cambridge, MA, United States, [6]Sobi, Stockholm, Sweden, [7]Sobi, Basel, Switzerland, [8]Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom

PO114

Monitoring of Albutrepenonacog alpha during invasive procedures in patients with hemophilia B.

S. Désage[1,*], C. Nougier[2], V. Chamouard[1], Y. Dargaud[1], S. Meunier[1], A. Lienhart[1]
[1]Hôpital cardiologique Louis Pradel, Hospices Civils de Lyon, Unité d'hémostase clinique, [2]Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Laboratoire d'hémostase, Lyon, France

PO115

Acquired haemophilia A and a difficult to treat inhibitor. Case report

S. Silva[1,*], D. Gonçalves[1], I. Moreira[1], L. Gonçalves[1], M. Carvalho[1], C. Koch[1]
[1]Center of Thrombosis and Haemostasis, Reference Center of Congenital Coagulopathies, Centro Hospitalar Universitário de São João, Porto, Portugal

PO116

Health-related Quality of Life in Adults With Hemophilia B After Gene Therapy With Fidanacogene Elaparvovec in the BENEGENE-2 Trial

S. von Mackensen[1,*], C. N. Bagot[2], A. Lienhart[3], F. Sahin[4], H. Tran[5], J. Rupon[6], A. Chhabra[7], M. Kalac[7], J. Fuiman[6], J. McKay[8], P. Sun[9], F. Plonski[6]
[1]Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, [2]Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom, [3]Hopital Cardiologique Louis Pradel – CRTH, Bron, France, [4]Ege University Medical Faculty Hospital, Izmir, Türkiye, [5]The Alfred Hospital, Melbourne, Australia, [6]Pfizer Inc, Collegeville, PA, [7]Pfizer Inc, New York, NY, [8]Pfizer Inc, Groton, CT, [9]Pfizer Inc, Cambridge, MA, United States

PO117

Acquired Hemophilia A: searching for probable causes.

T. Mota[1,*], R. Queirós[1], D. Carneiro-Leão[1], S. Fernandes[1], A. Leite[1], M. Koch[1]
[1]Reference Centre of Congenital Coagulopathies, Centro Hospitalar Universitário São João, Porto, Portugal

PO118

Reducing potential data gap after Gene Therapy using myGTR – a patient engagement tool from World Federation of Hemophilia Gene Therapy Registry

T. Youttananukorn[1,*], B. A. Konkle[2], F. Peyvandi[3], M. Naccache[1], W. Miesbach[4], B. O'Mahony[5], M. Makris[6], T. Matsushita[7], S. W. Pipe[8], T. Singleton[9], M. W. Skinner[10], D. Coffin[1], G. F. Pierce[1]
[1]World Federation of Hemophilia, Montreal, Canada, [2]University of Washington, Seattle, United States, [3]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, [4]University Hospital Frankfurt, Frankfurt, Germany, [5]Irish Haemophilia Society, Dublin, Ireland, [6]Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom, [7]Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan, [8]University of Michigan, Ann Arbor, Michigan, [9]American Thrombosis and Hemostasis Network, Rochester, [10]Institute for Policy Advancement Ltd, Washington DC, United States

PO119

CASE REPORT: TREATMENT FOR WOUND COMPLICATIONS OF EXTREMITY COMPARTMENT SYNDROME IN AN ACQUIRED HEMOPHILIA A PATIENT

T. D. B. Huynh[1,*], T. T. Tran[1]
[1]Cho Ray hospital, Ho Chi Minh, Viet Nam

PO120

Impacts on Functional Outcomes Following Total Knee Arthroplasty in Hemophilia Patients: A Comparative Study of Pain Catastrophizing and Adaptation to Artificial Joints

U. G. Kanlıkaya[1,*], G. I. Kınıklı[2], B. Göker[1], B. Atilla[1], Ö. Çağlar[1], A. M. Tokgözoğlu[1], S. Aksu[3]
[1]Orthopedics and Traumatology, [2]Physical Therapy and Rehabilitation, [3]Hematology, Hacettepe University, Ankara, Türkiye

PO121

Real-life single center experience on the effectiveness of Emicizumab prophylaxis in patients with Haemophilia A with and without inhibitors associated with improvement of health-related quality of life.

C. M. C. Sorbello[1], S. Grasso[1], U. Markovic[1,*], G. Sapuppo[1], G. Santuccio[1], F. Di Raimondo[1], G. Giuffrida[1]
[1]Hematology BMT Unity, AOU Policlinico G.Rodolico- S.Marco , Catania, Italy

PO122

Emicizumab in People with Moderate or Mild Haemophilia A Aged ≥40 Years, With and Without Comorbidities

V. Jiménez-Yuste[1,*], E. Tzeng[2], E. Lim[2], G. Ventriglia[3], A. Shapiro[4], J. Oldenburg[5], J. Mahlangu[6]
[1]La Paz University Hospital-IdiPaz, Autónoma University, Madrid, Spain, [2]Genentech, Inc., South San Francisco, United States, [3]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [4]Indiana Hemophilia & Thrombosis Center, Indianapolis, United States, [5]University Clinic Bonn, Bonn, Germany, [6]University of the Witwatersrand and NHLS, Johannesburg, South Africa

PO123

Treatment Preferences in Previously Treated Patients with Hemophilia A: Phase 3 XTEND-1 Study of Efanesoctocog Alfa

E. Spasov[1], D. Quon[2], K. Fukutake[3,4], J. Msihid[5], A. Willemze[6], J. Dumont[7], H. Palmborg[8], N. Kragh[8,*], A. Wilson[7]
[1]Clinic of Hematology, UMHAT St George and Medical University, Plovdiv, Bulgaria, [2]Orthopaedic Hemophilia Treatment Center, Luskin Orthopaedic Institute for Children, Los Angeles, United States, [3]Department of Laboratory Medicine, Tokyo Medical University, [4]Department of Blood Coagulation Diseases, Ogikubo Hospital, Tokyo, Japan, [5]Sanofi, Gentilly, France, [6]Sanofi, Amsterdam, Netherlands, [7]Sanofi, Cambridge, United States, [8]Sobi, Stockholm, Sweden

PO124

Seven-year follow-up of valoctocogene roxaparvovec gene therapy for haemophilia A

E. Symington[1,*], S. Rangarajan[2], W. Lester[3], B. Madan[4], G. F. Pierce[5], P. Raheja[6], C. Millar[7], D. Osmond[8], M. Li[8], T. M. Robinson[8]
[1]Cambridge University Hospitals NHS Foundation Trust, Cambridge, [2]Faculty of Medicine, University of Southampton, Southampton, [3]University Hospitals Birmingham NHS Foundation Trust, Birmingham, [4]Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, [5]Independent Consultant, La Jolla, United States, [6]Haemophilia Centre Royal London Hospital, Barts Health NHS Trust, [7]Imperial College Healthcare NHS Trust and Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, [8]BioMarin Pharmaceutical Inc., Novato, United States

PO125

French real-word data on rIX-FP prophylaxis use in adolescent-adult patients with haemophilia B

S. Castet[1], A. Fournel[2], B. Frotscher[3], D. Desprez[4], B. Gillet[5], B. Guillet[6,7], B. Tardy[8,9], A. Rauch[10], P. Chamouni[11], C. Biron-Andreani[12], A. Harroche[13], Y. Dargaud[14,15], C. Berger[8,16], B. Pan-Petesch[17], C. Reynes[18], J.-B. Valentin[19], R. d'Oiron[20,21], A. Hassoun[22], E. de Raucourt[23,24], A. Le Breton[25], V. Cussac[26], H. Catovic[27], C. Martin[27], F. Volot[28,*]
[1]HTC, Pellegrin Hospital, Bordeaux, [2]HTC, University Hospital, Besançon, [3]HTC, University Hospital, Nancy, [4]HTC, University Hospital, Strasbourg, [5]Haematology Laboratory and Haemophilia Reference Centre, Centre Hospitalier Universitaire de Caen, Caen, [6]HTC, University Hospital, [7]CHU Rennes, Inserm, EHESP, Irset - UMR_S 1085, F-35000 ,

University Rennes, Rennes, [8]HTC, University Hospital, [9]Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, [10]HTC, National Reference Willebrand Centre, University Hospital, Lille, [11]HTC, University Hospital, Rouen, [12]HTC, University Hospital, Montpellier, [13]HTC, Dep. of Hematology, University Hospital Necker Enfants Malades, Paris, [14]Clinical Haemostasis Unit, National Reference Center of Haemophilia, Louis Pradel Hospital, [15]UR 4609 Haemostasis and Thrombosis, Claude Bernard University, Lyon, [16]INSERM, U 1059, Lyon University, Jean Monnet University, Sainbiose, [17]HTC, Morvan University Hospital, Brest, [18]HTC, Hospital, Annecy, [19]HTC, University Hospital, Tours, [20]CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), Hôpital Bicêtre, AP-HP, Université Paris-Saclay, [21]HITh, UMR_S1176, INSERM, Université Paris-Saclay, Le Kremlin Bicêtre, Paris, [22]HTC, Simone Veil Hospital, GH Eaubonne-Montmorency, [23]HTC, Mignot Hospital, Versailles, [24]APHP, University Hospital Beaujon, Paris, [25]HTC, University Hospital, Clermont-Ferrand, [26]HTC, Hospital, Le Mans, [27]CSL Behring, Paris, [28]HTC Centre, Dijon Bourgogne University Hospital, Dijon, France

PO126

Emicizumab Prophylaxis in People with Haemophilia A: Summary of 10 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy

K. Sarouei[1], S. Barlera[2], L. Polito[3], G. Tobaruela[3,*], J. M. Biondo[1]
[1]Genentech, Inc., South San Francisco, United States, [2]Parexel International, Milan, Italy, [3]F. Hoffmann-La Roche Ltd, Basel, Switzerland

PO127

Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Interim Analysis in Paediatric Patients from the 24-Month, Prospective, Non-Interventional B-MORE Study

H. Glosli[1,*], H. Pergantou[2], B. Nolan[3], R. Berrueco[4], S. Ranta[5], M. Al Saleh[6], S. Lauer[7], E. Bednar[7], E. Gresko[8], E. Santagostino[8]
[1]Centre for Rare Disorders, Oslo University Hospital, Oslo, Norway, [2]Aghia Sophia Children's Hospital, Paediatric Haemophilia Centre/Haemostasis and Thrombosis Unit, Athens, Greece, [3]Children's Coagulation Centre, Children's Health Ireland at Crumlin, Dublin, Ireland, [4]Pediatric Hematology Department, Sant Joan de Déu Hospital, Barcelona, Spain, [5]Paediatric Coagulation Centre, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden, [6]King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, [7]Sobi, Stockholm, Sweden, [8]Sobi, Basel, Switzerland

PO128

The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study

J. Sun[1], Y. Chen[2], W. Li[3], R. Wu[4], Y. Feng'e[5], Z. Xiaojing[6], Z. Zeping[7], X. Bao[8], L. Xiaoyan[8], M. Zak[9,*], Y. Renchi[10]
[1]Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, [2]Jinan Central Hospital Affiliated to Shandong, First Medical University, Jinan, [3]Department of Haematology, Qinghai Provincial People's Hospital, Xining, [4]National Centre for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, [5]Fujian Institute of Haematology, Fujian Provincial Key Laboratory on Haematology, Fujian Medical University Union Hospital, Fuzhou, [6]Department of Haematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, [7]Department of Haematology, the Second Hospital Affiliated to Kunming Medical University, Kunming, [8]Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China, [9]Novo Nordisk A/S, Søborg, Denmark, [10]State Key Laboratory of Experimental Haematology, Tianjin, China

PO129

Comparing inhibitor development in (plasma derived vs recombinant) FVIII/FIX concentrates in severe haemophilia: reporting on 1392 PUPs from EUHASS and Canadian registries

K. Fischer[1,*], R. Lassila[2], F. Peyvandi[3], A. Gatt[4], R. Hollingworth[5], T. Lambert[6], R. Kaczmarek[7], A. Bettle[8], N. Samji[9], G. Rivard[10], M. Carcao[11], A. Iorio[9], M. Makris[12]

[1]UMC Utrecht, Utrecht, Netherlands, [2]Helsinki University Central Hospital, Helsinki, Finland, [3]University of Milan, Milan, Italy, [4]University of Malta, Msida, Malta, [5]MDSAS, Manchester, United Kingdom, [6]Hopital Bicetre, Paris, France, [7]University of Indiana, Indiana, United States, [8]IWK Health Centre, Halifax, [9]McMaster University, Hamilton, [10]Universite de Montreal, Montreal, [11]Hospital for Sick Children, Toronto, Canada, [12]University of Sheffield, Sheffield, United Kingdom

PO130

Uptake of emicizumab in PUPs with severe haemophilia A and changes in inhibitor incidence

K. Fischer[1,*], R. Lassila[2], F. Peyvandi[3], A. Gatt[4], S. Gouw[5], R. Hollingworth[6], T. Lambert[7], R. Kaczmarek[8], M. Makris[9]
[1]UMC Utrecht, Utrecht, Netherlands, [2]Helsinki University Central Hospital, Helsinki, Finland, [3]University of Milan, Milan, Italy, [4]University of Malta, Msida, Malta, [5]University of Amsterdam, Amsterdam, Netherlands, [6]MDSAS, Manchester, United Kingdom, [7]Hopital Bicetre, Paris, France, [8]University of Indiana, Indiana, United States, [9]University of Sheffield, Sheffield, United Kingdom

PO131

Healthcare resource use and related costs of Hemophilia B in French adult patients in 2021: a nationwide claims database analysis

L. FRENZEL [1,*], V. CAHOREAU[2], N. GIRAUD[3], S. DELIENNE[4], F. FAGNANI[5], S. BOUEE [5], J. COTTIN[5], I. BUREAU[5], J. RUDANT [6], A. REYNAUD[6], Y. FAHFOUHI[6], A. COUMERT[6], H. LILLIU [7], A. LEBRETON[8]
[1]APHP, Paris, [2]CHU Bordeaux, Bordeaux, [3]Association Française des Hémophiles, Paris, [4]CHU Dijon, Dijon, [5]CEMKA, Bourg-la-Reine, [6]Pfizer, Paris, France, [7]INBEO, London, United Kingdom, [8]CHU Clermont-Ferrand, Clermont-Ferrand, France

PO132

Vector Clearance Following Administration of Fidanacogene Elaparvovec Gene Therapy in Adults With Hemophilia B

L. Frenzel[1,*], H. Alzahrani[2], A. Cuker[3], J.-D. Wang[4], J. Fuiman[5], P. Sun[6], J. McKay[7], F. Biondo[8], P. Gaitonde[7], J. Smith[7], M. Kalac[9], J. Rupon[5], F. Plonski[5]
[1]Department of Haematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France, [2]King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, [3]Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, [4]Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan, Province of China, [5]Pfizer Inc, Collegeville, PA, [6]Pfizer Inc, Cambridge, MA, [7]Pfizer Inc, Groton, CT, United States, [8]Pfizer Srl, Rome, Italy, [9]Pfizer Inc, New York, NY, United States

PO133

Danish Clinical Experience of Switching from Standard Half-Life FVIII to Damoctocog Alfa Pegol in Patients with Haemophilia A

L. H. Poulsen[1,2,*], I. Adamsen[1,2]
[1]Department of Clinical Medicine, Aarhus University, [2]Haemophilia Centre, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark

PO134

Quality of Life in Children with Hemophilia A: Phase 3 XTEND-Kids Study of Efanesoctocog Alfa

M. Carcao[1,*], J. Staber[2], B. Nolan[3], A. Wilson[4], N. Kragh[5], G. Neill[6], L. Bystrická[5]
[1]Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Canada, [2]Department of Pediatrics, University of Iowa Stead Family Children's Hospital, Iowa City, United States, [3]Department of Paediatric Haematology, Children's Health Ireland at Crumlin, Dublin, Ireland, [4]Sanofi, Cambridge, United States, [5]Sobi, Stockholm, Sweden, [6]Sanofi, Reading, United Kingdom

PO135

The Effectiveness and Safety of Every-7-Days Damoctocog Alfa Pegol Prophylaxis in Hemophilia A in Phase 3, Phase 4 and Real-World Studies

M. T. Reding[1], P. A. Holme[2], M. T. Alvarez Román[3], R. De Cristofaro[4], M. Janbain[5], M. E. Mancuso[6,7,*]
[1]University of Minnesota Medical Center, Minneapolis, Minnesota, United States, [2]Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway, [3]Hospital Universitario La Paz, Madrid, Spain, [4]Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy, [5]Tulane School of Medicine, New Orleans, Louisiana, United States, [6]Center for Thrombosis and Haemorrhagic Disease, IRCCS Humanitas Research Hospital, Rozzano, [7]Humanitas University, Pieve Emanuele, Milan, Italy

PO136

Interim results from HA-SAFE: an observational study evaluating long-term safety of real-world treatment with damoctocog alfa pegol

J. Oldenburg[1], M. T. Alvarez Román[2,*], H. Pergantou[3], S. Wenning[4], M. E. Mancuso[5,6]
[1]University Clinic Bonn, Bonn, Germany, [2]Hospital Universitario La Paz, Madrid, Spain, [3]Agia Sophia General Children's Hospital of Athens, Athens, Greece, [4]Kurpfalzkrankenhaus Heidelberg, Heidelberg, Germany, [5]Center for Thrombosis and Haemorrhagic Disease, IRCCS Humanitas Research Hospital, Rozzano, [6]Humanitas University, Pieve Emanuele, Milan, Italy

PO138

Safety profile of damoctocog alfa pegol: fourth interim analysis of the real-world HEM-POWR study for previously treated patients with haemophilia A

M. T. Reding[1,*], M. T. Alvarez Román[2], G. Castaman[3], M. Janbain[4], T. Matsushita[5], K. Meijer[6], K. Schmidt[7], J. Oldenburg[8]
[1]University of Minnesota Medical Center, Minneapolis, United States, [2]Hospital Universitario La Paz, Madrid, Spain, [3]Careggi University Hospital, Milan, Italy, [4]Tulane School of Medicine, New Orleans, United States, [5]Nagoya University Hospital, Nagoya, Japan, [6]University Medical Center Groningen, Groningen, Netherlands, [7]Bayer, Berlin, [8]Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, Bonn, Germany

PO139

HEM-POWR study interim analysis four: effectiveness of damoctocog alfa pegol treatment for previously treated patients with haemophilia A

M. T. Reding[1,*], M. T. Alvarez Román[2], G. Castaman[3], M. Janbain[4], T. Matsushita[5], K. Meijer[6], K. Schmidt[7], J. Oldenburg[8]
[1]University of Minnesota Medical Center, Minneapolis, United States, [2]Hospital Universitario La Paz, Madrid, Spain, [3]Careggi University Hospital, Milan, Italy, [4]Tulane School of Medicine, New Orleans, United States, [5]Nagoya University Hospital, Nagoya, Japan, [6]University Medical Center Groningen, Groningen, Netherlands, [7]Bayer, Berlin, [8]Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, Bonn, Germany

PO140

Predicting time-dependent changes in factor VIII clearance in haemophilia A patients undergoing surgery.

A. Janssen[1,*] on behalf of OPTI-CLOT study group and SYMPHONY consortium, F. C. Bennis[2,3], I. van Moort[4], M. H. Cnossen[5], R. A. Mathôt[1] on behalf of for the OPTI-CLOT study group and SYMPHONY consortium
[1]Department of Clinical Pharmacology, Hospital Pharmacy, Amsterdam UMC, [2]Quantitative Data Analytics Group, Department of Computer Science, VU Amsterdam, [3]Department of Pediatrics, Emma Neuroscience Group, Emma Children's Hospital, Amsterdam UMC, Amsterdam, [4]Hematology, Erasmus University Medical Center, [5]Department of Pediatric Hematology, Erasmus MC Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, Netherlands

PO141

Associations between depression, anxiety, and stress with pain and joint status in patients with haemophilia

A. Schmidt[1,*], F. Tomschi[1], P. Ransmann[1], M. Bruehl[1], H. Richter[2], J. Oldenburg[3], A. Strauß[4], T. Hilberg[1]

[1]Department of Sports Medicine, University of Wuppertal, Wuppertal, [2]Haemophilia Center, Muenster, [3]Institute for Experimental Haematology and Transfusion Medicine, [4]Department of Orthopaedics and Trauma Surgery, University of Bonn, Bonn, Germany

PO142

Promising Future for Hemophilia A Patients: Is B-domain-deleted Factor VIII Gene Therapy Safe and Really Holds the Future?

A. P. Vidya[1,*], J. Jayadi[1], K. E. Utama[1], K. Ren[1], N. J. Wijaya[1]
[1]Faculty of Medicine, Universitas indonesia, Depok, Indonesia

PO143

Integration of a Clinical Research Unit and a Pediatric Hemophilia Unit: Recruitment and Follow-up of Pediatric Patients Participating in a Clinical Trial

J. Sanmartin Monserrat[1,*], N. Caballero Mencia[2], C. Llanos Príncipe[1], C. Benedicto Moreno[2], R. Berrueco Moreno[2]
[1]Clinical Research Unit, Sant Joan de Déu Research Fundation, [2]Thrombosis and Hemostasis Unit, Hospital Sant Joan de Déu, Barcelona, Spain

PO144

Health-related quality of life and long-term joint damage in people with severe Haemophilia A in Brazil

J. Evans[1,*], T. Burke[1]
[1]HCD Economics, Knutsford, United Kingdom

PO145

Real World Evidence: Experience Of Using Standard Half-Life Factors With Frequency Less Than Twice A Week In Hemophilia A

J. Wilches[1,*], D. R. Arias[2], D. Burgos[1]
[1]Área Médica, [2]Gerencia, IPS Especializada, Bogotá D.C., Colombia

PO146

Real-world Bleeding Rates on Emicizumab using Digital Treatment Diary data, preliminary results

M. Brands[1,*], L. Taal[2,3], M. Driessens[4], C. van Veen[3], M. Kruip[5], P. den Exter[6], B. Laros-van Gorkom [7,8], M. Stein-Wit [9], K. Fischer[10], S. Meijer[4], K. Meijer[11], M. Beijlevelt [1], K. Fijnvandraat[1,12], S. Gouw[1,13]
[1]Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC location University of Amsterdam, Amsterdam, [2]Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, [3]HemoNED Foundation, Leiden, [4]Netherlands Hemophilia Patient Society (NVHP), Nijkerk, [5]Department of Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, [6]Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, [7]Department of Hematology, Radboud University Medical Center, [8]Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, [9]Department of Pediatrics, University Medical Center Groningen, Groningen, [10]Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht, [11]Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, [12]Department of Molecular Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam, [13]Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands

PO147

Quality of Life Assessment and Pharmacokinetic Study in Hemophilia A Patients Undergoing Prophylactic Treatment

N. Kotsiou[1,*], E. Gavriilaki[1], S. Chissan[1], Z. Ntova[1], E. Moka[1], S. Aivazidou[1], A. Katsetsiadis[1], P. Kalmoukos[1], S. Vakalopoulou[1]
[1]Hemophilia Center of Northern Greece, Thessaloniki, Greece

PO148

Real world experience using emicizumab in pediatric patients: clinical features and joint health evaluation

P. Estival-Monteliú[1,2,3,*], N. Caballero[1,2,3], C. Benedicto[1,2,3], N. Rodriguez-Nieva[2,3,4], R. Berrueco[1,2,3]
[1]Pediatric Hematology Department, [2]Institut de Recerca Sant Joan de Déu (IRSJD), Hospital Sant Joan de Déu, [3]CSUR coagulopatías. Eurobloodnet member, Integrated Hemophilia Unit SJD-HSP, [4]Pediatric Rehabilitation Department, Hospital Sant Joan de Déu, Barcelona, Spain

PO150

ACQUIRED HAEMOPHILIA - CLINICAL MANIFESTATIONS AND MANAGEMENT; A SINGLE CENTRE EXPERIENCE

A. Kouramba[1,*], M. Gavalaki[1], A. Zannou[1], A.-I. Gkioka[1], K. Valera[1], E. Theodorou[1], O. Katsarou[1]
[1]Blood unit and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Athens, Greece, Athens, Greece

PO152

CLINICAL OUTCOMES OF PROPHYLAXIS WITH EXTENDED HALF-LIFE COAGULATION FACTOR CONCENTRATES OR EMICIZUMAB IN HAEMOPHILIA

L. Fernandez Cuezva[1], R. Gonzalez Resina[1], J. Obregon Membreño[1], F. Olivo Moreno[1], L. Etxebarria Bahillo[1], L. Villarroya Martinez[1], M. S. Ordas Miguelez[1], P. Lopez Gomez[1], M. Herrero Gutierrez[1], R. Monleon Gil[1], F. Cadenas Gota[1], R. Palacios Orellana[1], D. F. Lozada Poveda[1], N. Fernandez Mosteirin[1], J. M. Calvo Villas[1,*]
[1]Hematología y Hemoterapia, Hospital Universitario Miguel Servet, Zaragoza, Spain

PO153

POSITIVE CLINICAL IMPACT AFTER SWITCHING TO TUROCTOCOG ALFA PEGOL: IBERIAN EXPERIENCE

O. Benítez Hidalgo[1,*], F. J. López Jaime[2], N. F. Pérez González[3], M. Canaro Hirnyk[4], C. Aguilar Franco[5], A. Delgado García[6], M. C. Fernández Sánchez de Mora[7], M. C. Gómez del Castillo Solano[8], J. R. Gónzalez Porras[9], S. Marcellini Antonio[10], A. Marco Rico[11], M. D. M. Nieto[12], M. Rodríguez López[13], S. Nobre Fernandes[14]
[1]Hematology, Hospital Universitari Vall d'Hebron, Barcelona, [2]Hematology, Hospital Regional Universitario de Málaga,, Málaga, [3]Hematology, Hospital Torrecárdenas, Almería, [4]Hematology, Hospital Universitari Son Espases, Palma de Mallorca, [5]Hematology, Hospital Santa Bárbara, Soria, [6]Hematology, Hospital Universitario Virgen de las Nieves, Granada, [7]Hematology, Hospital Universitario Reina Sofia, Córdoba, [8]Hematology, Hospital Universitario de A Coruña, A Coruña, [9]Hematology, Complejo Asistencial Universitario de Salamanca, Salamanca, [10]Hematology, Complejo Asistencial de Segovia, Segovia, [11]Hematology, Hospital General Universitario de Alicante, Alicante, [12]Hematology, Complejo Hospitalario de Jaén, Jaén, [13]Hematology, Hospital Álvaro Cunqueiro, Vigo, Spain, [14]Hematology, Centro Hospitalar e Universitário de São João, Porto, Portugal

PO154

REAL WORLD USE OF SIMOCTOCOG ALFA IN PERSONS WITH HAEMOPHILIA A (PwHA) IN SPAIN

O. Benítez Hidalgo[1,*], F. J. López Jaime[2], A. Caro Gómez[3], M. Canaro[4], L. Fernández Cuezva [5], A. León Mendoza[6], A. Marco Rico[7], M. Rodríguez López[8], M. T. Álvarez Román[9]
[1]Hematology, Hospital Universitari Vall d'Hebron, Barcelona, [2]Hematology, Hospital Regional Universitario de Málaga, Málaga, [3]Hematology, Hospital Universitario Central de Asturias, Oviedo, [4]Hematology, Hospital Universitario Son Espases, Palma de Mallorca, [5]Hematology, Hospital Universitario Miguel Servet, Zaragoza, [6]Hematology, Hospital Nuestra Señora de Guadalupe, La Gomera, [7]Hematology, Hospital General Universitario de Alicante, Alicante, [8]Hematology, Hospital Álvaro Cunqueiro, Vigo, [9]Hematology, Hospital Universitario La Paz, Madrid, Spain

PO155

PHARMACOKINETIC ANALYSIS IN PATIENTS WITH HEMOPHILIA A IN PROPHYLAXIS WITH TUROCTOCOG ALFA PEGOL IN ONE CENTRE IN SPAIN

O. Benítez Hidalgo[1,*], S. Camarillas Carmona[1], J. C. Juarez Gimenez[2]
[1]Hematology, [2]Pharmacy, Hospital Universitari Vall d'Hebron, Barcelona, Spain

PO156

Tele-psychological intervention for people diagnosed with haemophilia

V. M S [1], S. Hanagavadi[2,*], P. V. Bhandary[2], M. E R[1], N. Murthy[1]
[1]Psychiatry, Dr.A V Baliga Memorial Hospital , Udupi, [2]Pathology, JSS Medical College, Davangere, India

PO157

The Use of the Haemophilia Joint Health Score As a Monitoring Tool for Children with Severe Haemophilia A on Emicizumab Prophylaxis

Z. Jaffer[1,*], K. Reynolds[1], N. Lawson[1], J. Motwani[1]
[1]Paediatric Haemophilia Unit, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, United Kingdom

PO158

Experience of Treatment in Children with Severe Hemophilia B in a single center

C. Gil Barroso[1,*], P. Pérez García[1], B. Díaz Roldán[1], J. F. Domínguez Rodríguez [1]
[1]Haematology, Hospital Juan Ramón Jiménez, Huelva, Spain

PO159

Development of a core data set for individual treatment plans for patients with congenital bleeding disorders

C. Van Veen[1,*], E. Taal[1,2], M. Brands[3], M. Driessens[4], M. Kruip[5], K. Fischer[6], M. Beijlevelt[3], S. Gouw[2,3]
[1]HemoNED Foundation, [2]Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, [3]Pediatric Hematology, , Emma Children's Hospital, Amsterdam UMC location University of Amsterdam, Amsterdam, [4]NVHP, Nijkerk, [5]Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, [6]Center for Benign Haematology, Thrombosis and Haemostasis,, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

PO160

SARS-CoV-2 VACCINATION IN HEMOPHILIA PATIENTS, A SINGLE CENTRE EXPERIENCE

J. Bodrozic[1,2,*], S. Vlajin[1]
[1]Cabinet for hemostasis and thrombosis, Hematology Clinic, University Clinical Center of Serbia, [2]Faculty of Medicine, University of Belgrade, Belgrade, Serbia

PO161

The MAPTO survey, Mapping Approaches to Tolerance in PUP/MTP treatment around the world in the non-replacement era

L. E. van Stam[1,*], P. Angchaisuksiri[2], M. D. Carcao[3], G. Kenet[4], C. Königs[5], J. Mahlangu[6], M. E. Mancuso[7], S. M. Rezende[8], R. F. Sidonio Jr.[9], S. Sivapalaratnam[10], A. Srivastava[11], G. Young[12], K. Fijnvandraat[1,13], S. C. Gouw[1]
[1]Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, [2]Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, [3]Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada, [4]Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, [5]Department of Pediatrics and Adolescent Medicine, Clinical and Molecular Hemostasis, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, [6]Department of Molecular Medicine and Hematology, Faculty of Health Sciences, Hemophilia Comprehensive Care Centre, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa, [7]Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy, [8]Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil,

[9]Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States, [10]Blizard Institute, Queen Mary University London, London, United Kingdom, [11]Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India, [12]Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, United States, [13]Department of Molecular Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands

PO162

Characteristics of Girls with haemophilia A or B included in the PedNet registry

M. de Kovel[1,*], B. Nolan[2], J. Motwani[3], E. de Boer-Verdonk[1], N. G. Andersson[4,5], J. Oldenburg[6], E. Zapotocka[7], K. Fischer[8], R. d'Oiron[9] on behalf of PedNet Study Group
[1]PedNet Haemophilia Research Foundation, Baarn, Netherlands, [2]Children's Health Ireland at Crumlin, Dublin, Ireland, [3]Department of Haematology, Birmingham Children's Hospital, Birmingham, United Kingdom, [4]Department of Clinical Sciences and Pediatrics, Center for Thrombosis and Hemostasis, Skane University Hospital, Malmö, [5]Lund University, Lund, Sweden, [6]Institute of Experimental Hematology and Transfusion Medicince, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany, [7]Department of Paediatric Haematology/Oncology, University Hospital Motol, Prague, Czech Republic, [8]Center for Benign Haematology, Thrombosis and Haemostasis Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands, [9]Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles rares, Hôpital Bicêtre AP-HP, et INSERM Hémostase inflammation thrombose HITH U1176, Université Paris-Saclay, Le Kremlin-Bicêtre, France

PO163

Gathering and Disseminating Standardized Gene Therapy Data – The World Federation of Hemophilia Gene Therapy Registry

B. A. Konkle[1], F. Peyvandi[2], M. Naccache[3,*], T. Youttananukorn[3], W. Miesbach[4], B. O'Mahony[5], M. Makris[6], T. Matsushita[7], S. W. Pipe[8], T. Singleton[9], M. W. Skinner[10], D. Coffin[3], G. F. Pierce[3]
[1]University of Washington, Seattle, United States, [2]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, [3]World Federation of Hemophilia, Montreal, Canada, [4]University Hospital Frankfurt, Frankfurt, Germany, [5]Irish Haemophilia Society, Dublin, Ireland, [6]Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom, [7]Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan, [8]University of Michigan, Ann Arbor, [9]American Thrombosis and Hemostasis Network, Rochester, [10]Institute for Policy Advancement Ltd, Washington, United States

PO164

The World Federation of Hemophilia Living Guidelines Model

M. Mayla[1], D. Coffin[1,*], E. Gouider[2,3], G. F. Pierce[3], S. Zelman-Lewis[4], T. Schofield[4]
[1]Research and Education, WFH, Montreal, Canada, [2]ôpital Aziza Othmana – Université Tunis El Mana, Tunis, Tunisia, [3]WFH, Montreal, Canada, [4]EBQ Consulting, Chicago, United States

PO165

Body composition in patients with haemophilia and the impact of severity phenotype and age

P. Ransmann[1,*], M. Brühl[1,2], J. Hmida[1,2], G. Goldmann[3], F. Tomschi[1], J. Oldenburg[3], T. Hilberg[1], A. Straußß[2]
[1]Department of Sports Medicine, University of Wuppertal, Wuppertal, [2]Department of Orthopedics and Trauma Surgery, [3]Institute for Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

PO166

Psychometric evaluation of the Haem-A-QoL in adults with haemophilia B

S. Thakkar[1,*], A. K. Kawata[2], A. G. Bushmakin[1], W. R. Lenderking[3], J. C. Cappelleri[1], M. Ines[1], V. Melin[1], P. Daniele[4], C. Clucas[5]

[1]Pfizer, New York, [2]Evidera, Bethesda, [3]Evidera, Waltham, United States, [4]Evidera, Saint-Laurent, Canada, [5]Evidera, London, United Kingdom

PO167

The Haemophilia Activities List: psychometric evaluation in adults with haemophilia B

S. Thakkar[2,*], A. K. Kawata[1], A. G. Bushmakin[2], W. R. Lenderking[3], J. C. Cappelleri[2], M. Ines[2], V. Melin[2], P. Daniele[4], C. Clucas[5]
[1]Evidera, Bethesda, [2]Pfizer, New York, [3]Evidera, Waltham, United States, [4]Evidera, Saint-Laurent, Canada, [5]Evidera, London, United Kingdom

PO168

Ultrasound in Hemophilia and Sports: Detection of Bleedings and Safe Return to Sport determination

A. Nally[1,*], F. Nally[2], F. Morales[3], G. Dolabella[4], M. Martinez[5], G. Sliba[5]
[1]Radiology, [2]Traumathology, [3]biochemical, [4] odontology, [5]hematology, Fundacion Hemofilia MdQ, Mar del Plata, Argentina

PO169

Risks of Ignoring Limits in Non Severe Haemophilia : Advantages of the Interdisciplinary Team in Emergency Management

A. P. Nally[1,*], G. Sliba[2], F. Morales[3], F. Nally[4], G. Dolabella[5], M. Martinez[2]
[1]Radiology, [2]hematology, [3]biochemical, [4]Traumathology, [5] odontology, Fundacion Hemofilia MdQ, Mar del Plata, Argentina

PO170

Healthcare resource use and related costs of Hemophilia A in French adult patients in 2021: a nationwide claims database analysis

A. LEBRETON[1,*], V. CAHOREAU[2], N. GIRAUD[3], S. DELIENNE[4], F. FAGNANI[5], S. BOUEE[5], J. COTTIN[5], I. BUREAU[5], J. RUDANT [6], A. REYNAUD[6], L. MARTIN[6], A. COUMERT[6], H. LILLIU [7], L. FRENZEL [8]
[1]CHU Clermont-Ferrand, Clermont-Ferrand, [2]CHU Bordeaux, Bordeaux, [3]Association Française des Hémophiles, Paris, [4]CHU Dijon, Dijon, [5]CEMKA, Bourg-la-Reine, [6]Pfizer, Paris, France, [7]INBEO, London, United Kingdom, [8]APHP, Paris, France

PO171

The Evaluation of Joint Health and Health-Related Quality of Life in Children with Hemophilia: A Cross-Sectional Single-Center Study

A. Unuvar[1,*], B. Gunyel[2], G. Baskent[3], M. Bulakci[4]
[1]Division of Pediatric Hematology&Oncology, [2]Department of Pediatrics, [3]Department of Physiotherapy, [4]Department of Radiology, Istanbul University, Istanbul School of Medicine, Istanbul, Türkiye

PO172

Inhibitor Development in Mild Hemophilia A: Four Patients

C. Albayrak[1,*], D. Albayrak[2]
[1]Pediatric Hematology, Ondokuz Mayıs University Medical Faculty, [2]Pediatric Hematology , Samsun Medicalpark Hospital, Samsun, Türkiye

PO173

Real -World Experience of Emicizumab Prophylaxis in Children with Severe Hemophilia A: I year Follow-up Study in Egypt

L. Sherief[1,*] on behalf of Ahmed S Hassan, Mona Hamdy, Ahmad Darwish, Amira Nazim, Mohamed A Hussein , Mohamed R Elgendy, Osama A El-assy
[1]Pediatric, Zagazig University, zagazig, Egypt

PO174

Successful Management of Haematuria With Bypassing Agents For Paediatric Congenital Haemophilia A With Inhibitor: A Case Report And Literature Review

M. Soker[1,*], V. H. Uzel[1]
[1]Pediatric Hematology and Oncology, Dicle University Medical Faculty, Diyarbakır, Türkiye

PO175

Long-Term analysis of Real Clinical Practice of Emicizumab treatment in Patients with Severe Hemophilia A with and without FVIII Inhibitors

N. Zozulya[1,*], O. Dimitrieva[1], E. Yakovleva[1]
[1]Hemostasis Disorders, National Medical Research Center for Hematology, Moscow, Russian Federation

PO176

Hacettepe experience including circumsission with extended half-life Factor VIII fusion protein(rFVIIIFc) that has recently become available in Turkiye

S. Aytac[1,*], Ö. Albayrak[2], S. Ay[2], E. Zeytinoglu[2], Z. Ozeren[2], T. Soyer[3]
[1]Department of Pediatric Hematology, [2]Department of Pediatrics, [3]Department of pediatric Surgery, Hacettepe University Faculty of Medicine , Ankara, Türkiye

PO177

Carriers – The great psychological darkness beyond bleeding events

S. Halimeh[1,*], D. Heinrichs[1]
[1]Gerinnungszentrum Rhein Ruhr, Duisburg, Germany

PO178

Optimizing Joint Health in Hemophilia Patients:
Insights from a Retrospective Cohort Study

S. Halimeh[1,*], M. Siebert[2], A. Daoud[3]
[1]Gerinnungszentrum Rhein Ruhr, Duisburg, Germany, [2]Haemophilia, Gerinnungszentrum Rhein Ruhr, [3]HRC Gmbh, Duisburg, Germany

PO179

USE OF LOW-DOSE ELOCTA® THREE TIMES A WEEK IN PROPHYLAXIS IN A VOLLEYBALL PLAYER PATIENT WITH SEVERE HEMOPHILIA A

Y. I. Balcı[1,*], Y. Z. Aral [1], M. Akcan[1], Ö. Cartı[1]
[1]Department of Pediatric Hematology and Oncology, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Türkiye

PO180

The Characteristics and Treatment Patterns in Hemophilia B Patients Receiving Recombinant Coagulation Factor IX

Y. S. Park[1,*], T. J. Hwang[2], S. K. Park[3], E. J. Choi[4], J. A. Park[5], H. J. Baek[6], C. J. Lyu[7], J. H. Lee[8], M. K. Kim[9], J. Y. Kim[10], S. A. Lee[11], B. Park[12], D.-H. Kim[12], S. B. Chung[12], C.-M. Nam[13], Y. Lee[14], K. Y. Yoo[15]
[1]Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, [2]Korea Hemophilia Foundation Clinic, Gwangju, [3]Korea Hemophilia Foundation Clinic, Busan, [4]Department of Pediatrics, Daegu Catholic University Medical

Center, Daegu, [5]Department of Pediatrics, Inha University Hospital, Incheon, [6]Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Chonnam, [7]Department of Pediatric Hematology Oncology, Yonsei University College of Medicine, Seoul, [8]Department of Pediatrics, Chungbuk National University School of Medicine, Chungbuk National University Hospital, Cheongju 28644, [9]Department of Pediatrics, Presbyterian Medical Center, 365 Seowon-ro, Wansan-gu, Jeonju 54987, [10]Department of Pediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, [11]Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, [12]Medical Department, Pfizer Pharmaceuticals Korea Ltd, [13]Department of Preventive Medicine, Yonsei University College of Medicine, [14]Department of Biostatistics and Computing, Yonsei University, [15]Korea Hemophilia Foundation Clinic, Seoul, Korea, Republic Of

PO181

The Histopathological Landscape of Synovitis in Hemophilic Arthropathy

R. Gualtierotti[1,2,*], A. Giachi[2], C. Suffritti[1], C. Pescia[2,3], S. Arcudi[1], A. Ciavarella[1,4], M. Maggioni[5], U. Gianelli[6,7], S. M. Siboni[1], J. Acquati Lozej[8], L. P. Solimeno[8], F. Peyvandi[1,2]
[1]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [2]Department of Pathophysiology and Transplantation, Università degi Studi di Milano, [3]Unit of Anatomic Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [4]Department of Biomedical Sciences for Health, Università degi Studi di Milano, [5]Unit ofAnatomic Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [6]Unit of Anatomic Pathology, ASST Santi Paolo e Carlo, [7]Department of Health Sciences, Università degli Studi di Milano, [8]Division of Orthopedic Surgery and Traumatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

PO182

Simulation of Extended Half-Life Replacement FIX Therapy Dosing to Achieve Comparable FIX activity to that of Fidanacogene Elaparvovec Gene Therapy in Haemophilia B Patients

J. Wojciechowski[1], P. Gaitonde[1,*], L. Wilcox[2]
[1]Pfizer, Inc, Groton, United States, [2]Pfizer, Inc, Toronto, Canada

PO183

Women living with bleeding disorders: Insights from a Nordic survey study

A. Olsson[1], E. Funding[2], L. Hvitfeldt Poulsen[3], T. Szanto[4,5], H. Knudsen[6], T. Andersson[7], A. Tjärnlund-Wolf[7], S. Meisgen[7], R. Lassila[4,5,*]
[1]Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, [2]Department of Haematology, Rigshospitalet, Copenhagen, [3]Department of Hematology, Haemophilia Center, Aarhus University Hospital, Aarhus, Denmark, [4]Comprehensive Cancer Center, Coagulation Disorders Unit, Helsinki University Hospital, [5]Faculty of Medicine, Research Program Unit in Systems Oncology, Helsinki University, Helsinki, Finland, [6]Center for Rare Disorders, Oslo University Hospital, Oslo, Norway, [7]CSL Behring AB, Stockholm, Sweden

PO184

Systematic literature review to evaluate hemophilia A therapies in pediatric patients without inhibitors

R. Sidonio[1,*], R. Kulkarni[2], J. Motwani[3], A. Wilson[4], P. Guyot[5], A. Fernandez[6], N. Kragh[7], L. Bystrická[7], A. Arnaud[4]
[1]Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, [2]Department of Pediatrics and Human Development, Michigan State University, East Lansing, United States, [3]Department of Paediatric Haematology, Birmingham Children's Hospital, Birmingham, United Kingdom, [4]Sanofi, Cambridge, United States, [5]Sanofi, Gentilly, France, [6]Sanofi, Zug, Switzerland, [7]Sobi, Stockholm, Sweden

PO185

HIV Comorbid Infection and Etranacogene Dezaparvovec Therapy: Efficacy and Safety Results From Phase 2b and Pivotal Phase 3 HOPE-B Trials 3 Years after Administration

S. Pipe[1,*], E. Gomez[2], C. Hermans[3], A. Giermasz[4], P. Kampmann[5], R. Lemons[6], N. Galante[7], S. Le Quellec[7], P. Monahan[7]
[1]University of Michigan, Ann Arbor, [2]The Center for Inherited Blood Disorders, Orange, United States, [3]Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium, [4]Department of Medicine, Division of Hematology and Oncology, Hemophilia Treatment Center, University of California Davis, Sacramento, United States, [5]Rigshospitalet, Copenhagen, Denmark, [6]University of Utah, Salt Lake City, [7]CSL Behring, King of Prussia, United States

PO186

Immunogenicity and safety of marstacimab, an anti-tissue factor pathway inhibitor, in participants with hemophilia A or B and without inhibitors

S. S. Acharya[1], C. T. Taylor[2], E. Hwang[3], T. Hinnershitz[4], S. V. Raje[3], E. Mefyod[5], A. Palladino[3], F. Biondo[6,*], J. Teeter[4]
[1]Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, NY, [2]Pfizer Inc, New York, NY, [3]Pfizer Inc, Collegeville, PA, [4]Pfizer Inc, Groton, CT, United States, [5]Pfizer Inc, Smolensk, Russian Federation, [6]Pfizer Srl, Rome, Italy

PO187

Genetic Diagnosis of Von Willebrand Disease: Preliminary results

B. Koc[1,*], S. Kılıc Erciyas[2], B. Tuncer[2], B. Zulfikar[1]
[1]Department of Pediatric Hematology /Oncology, [2]Basic Oncology, Department of Cancer Genetics, Istanbul University Oncology Institute, Istanbul, Türkiye

PO188

Evaluation of thrombin generation assay profiles in patients with von Willebrand disease

A. Majsec[1], I. Lapić[2], D. Coen Herak[1,2,*], M. Miloš[2,3], S. Dejanović Bekić[4], A. Boban[5], E. Bilić[4]
[1]Faculty of Pharmacy and Biochemistry, University of Zagreb, [2]Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia, [3]Faculty of Pharmacy, University of Mostar, Mostar, Bosnia and Herzegovina, [4]Department of Pediatrics, [5]Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

PO189

Frequency of Type 2N vWD Among Patients with Mild or Moderate Factor VIII Deficiency in Iran

B. Azari[1,*], M. Ahmadinejad[1]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO190

Clinical pharmacokinetic analysis of VWF parameters following FVIII/VWF concentrates in patients with immune-mediated aVWS: a case series

S. De Bruijn[1,*], I. Vangenechten[1,2], A. Gadisseur[1,2]
[1]Hematology, [2]Hemostasis and Thrombosis Research Center, Antwerp University Hospital, Antwerp, Belgium

PO191

The relation between heavy menstrual bleeding, menstrual phases and plasma clotting factor concentration: a systematic review and meta-analysis

A. de Vaan[1], M. M. Goedkoop[1], P. M. Welsing[2], R. T. Urbanus[1,3], J. van Leeuwen[4], R. E. Schutgens[1], K. P. van Galen[1,*]
[1]Center for Benign Hematology, Thrombisis and Hemostasis, van Creveldkliniek, [2]Department of Rheumatology & Clinical Immunology, [3]Circulatory Health Research Center, [4]Department of Reproductive Medicine & Gynaecology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

PO192

The use of protein A-conjugated magnetic nanoparticles in the von Willebrand factor purification technology

N. Shurko[1,*], T. Danysh[1]
[1]State Institution "Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine", Lviv , Ukraine

PO193

Females with Von Willebrand disease: The silent majority in Brazil

Y. M. D. S. Pires[1,*]
[1]Pharmaceutical Sciences, UFPR, Curitiba, Brazil

PO194

Managing von Willebrand disease with inhibitors during prophylaxis with a plasma derived von Willebrand Factor/Factor VIII concentrate – The WIL-31 study

C. D. Khayat[1,*], R. F. Sidonio[2], A. Pavlova[3]
[1]Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon, [2]Department of Pediatrics, Emory University School of Medicine, Atlanta, United States, [3]Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany

PO195

Hypersensitivity to von Willebrand factor and von Willebrand disease. A case-report.

D. Carneiro-Leão[1,*], R. Queirós[1], T. Mota[1], S. Fernandes[1], M. Lopes[1], M. D. C. Koch[1]
[1]Department of Immunohemotherapy, Centre of Thrombosis and Hemostasis, Congenital Coagulopathies Reference Centre, Centro Hospitalar Universitário de São João, E.P.E., Porto, Portugal, Porto, Portugal

PO196

Von Willebrand disease in children and adolescents.
A single center experience

A. Adramerina[1], M. Vousvouki[1], M. Ziaka[1], C. Gibriksis[1], S. Gerou[1], A. Teli[1,*], M. Economou[1]
[1]1st Pediatric Department, Aristotle University of Thessaloniki, Thessaloniki, Greece

PO197

Cost model of long-term prophylaxis with von Willebrand Factor concentrate

A. Palomero[1,*], J. M. Calvo[2]
[1]Farmacia, Hospital Universitari Son Espases, Palma de Mallorca, [2]Hematologia, Hospital Universitario Miguel Servet, Zaragoza, Spain

PO198

Von Willebrand Disease diagnostic situations in pediatric patients, a study from the FranceCoag Registry

A. F. Petit[1,*], C. Tabele[1], H. Chambost[1], S. Bayart[2], C. Galeotti[3], A. Harroche[4], Y. Huguenin[5], C. Oudot Challard[6], Y. Repesse[7], S. Susen[8], C. Falaise[1] on behalf of For the FranceCoag Network
[1]APHM Marseille, Marseille, [2]CHU Rennes, Rennes, [3]Hopital Bicêtre , [4]Hopital Necker, Paris, [5]CHU de Bordeaux, Bordeaux, [6]CHU de Toulouse, Toulouse , [7]CHU de Caen, Caen , [8]CHRU Lille, Lille, France

PO199

Acquired von Willebrand syndrome and molecular targeted anticancer therapy : about a case.

J. Wimmer[1], E. Hammami[2], L. Sattler[1], O. Feugeas[3], E. Jeanpierre[4], D. Desprez[3,*]

[1]Haematology Laboratory, Strasbourg University Hospitals, Strasbourg, [2]Haematology Laboratory, Mulhouse Hospital, Mulhouse, [3]Haemophilia Treatment Center, Strasbourg University Hospitals, Strasbourg, [4]Haematology Laboratory, Lille University Hospitals, Lille, France

PO200

Treatment issues in bleeding and acute thrombotic event scenario in elderly patients with inherited bleeding disorders. A case report.

I. Moreira[1,*], L. Costa[1], M. Carvalho[1], S. Silva[1], D. Gonçalves[1], I. Marques[1], M. Lopes[1], S. Fernandes[1], C. Koch[1]
[1]Center of Thrombosis and Haemostasis, Reference Center of Congenital Coagulopathies, Centro Hospitalar Universitário São João, Porto, Portugal

PO201

Von Willebrand Disease in Association with Neurodevelopmental Disorder - A Rare Case Report

K. Mohandass[1,*], P. Murugasamy[2], G. Mohan[3]
[1]Medical genetics, GeneOmm Medical Centre, [2]Medical genetics, KMCH Institute of Health Sciences and Research, [3]Biotechnology, Karpagam Academy of Higher Education, Coimbatore, India

PO202

A case report of type-2B Von Willebrand Disease and gastrointestinal bleeding

M. N. Alonso Escobar[1,*], P. Sánchez Risco[1], C. L. Crespo Nuñez[1], C. A. Guillén Sarmiento[1], M. B. Moreno Risco[1], E. Jurado Vinteño[1], D. Varea Calero[1], A. Hurtado Villanueva[1], R. Rincón Ferrari[1], J. M. Vagace Valero[1]
[1]Badajoz University Hospital Complex, Badajoz, Spain

PO203

Challenges in Managing Severe Von Willebrand Disease: Insights from Algiers Centre

M. Bensadok[1,*], N. Ferroudj[1], M. Terchi[1], N. Zidani[1], S. Nekkal[1]
[1]hematology,blood bank, Hospital Benimessous, Algiers, Algeria

PO204

Prevalence of von Willebrand Disease among women with Heavy Menstrual Bleeding

P. Kharab[1,*], D. Sarwan[1], R. Goswami[1], M. Masih[1], P. DS[1], M. Gupta[1], V. Chaudhary[1], K. Vats[1], W. Joyal[1], P. Byreddy[2], J. John[1]
[1]Department of Clinical Haematology, Haemato- oncology and Bone Marrow (Stem Cell) Transplantation, Christian Medical College and Hospital, Ludhiana, [2]Department of Haematology, CARE Hospitals, Hyderabad, India

PO205

Lenalidomide has its place in the treatment of acquired Von Willebrand disease

S. Herrero[1,*], V. Alonso[1], I. Nuevo[1], A. Santos[1]
[1]Hematology, Universitary Guadalajra Hospital, Guadalajara, Spain

PO206

Recombinant von Willebrand factor treatment outcomes in UK adults with von Willebrand disease: A retrospective chart review study

O. Heard[1,*], M. Laffan[2], C. Jones[3], A. Sanigorska[3], S. Brighton[3], R. Willock[3], H. Howitt[1]
[1]Takeda UK Ltd, [2]Hammersmith Hospital, London, [3]HCD Economics, Daresbury, United Kingdom

PO207

Successful control of bleeding in a patient with acquired von Willebrand syndrome using high-purity human von Willebrand factor

W. Maposa[1,*], A. Alaro[1], H. Larkin[1], C. Brown[1], P. Kanagasabapathy[1], K. Feane[2], A. Haile[3], S. Austin[1]
[1]Haemophilia, [2]Transfusion, [3]Coagulation Laboratory, St Georges University Hospitals , London, United Kingdom

PO208

MANAGEMENT OF WOMEN WITH INHERID BLEEDING DISORDERS DURING PREGNANCY; A SINGLE CENTRE EXPERIENCE

A. Kouramba[1,1,*], A. Kotsiafti[1], M. Gavalaki[1], K. Valera[1], A.-I. Gkioka[1], I. Anastasopoulou[1], A. Balomenou[1], O. Katsarou[1]
[1]Blood Transfusion Service and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Athens, Greece, athens, Greece

PO209

A series of Unfortunate Events- Case study of challenging vaginal bleed management associated with Type 2 von Willebrand Disease (vWD).

C. Foley[1,*], A. Morris[1], H. Williams[1], P. Raheja[1], K. Forsyth[1]
[1]Haemophilia Comprehensive Care Centre, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom

PO210

Efficacy and Safety of Plasma-derived VWF Concentrates in a cohort of 93 Patients with Type 3 von Willebrand Disease enrolled in 3WINTERS-IPS: Results of the 2-year Prospective Clinical Observation

A. B. Federici[1,*] on behalf of 3Winters-Ips Investigators
[1]L. Sacco University Hospital, University of Milan, Milan, Italy

PO211

MANAGEMENT OF HEAVING BLEEDING MENSTRUAL IN PATIENTS WITH VON WILLEBRAND DISEASE. EXPERIENCE OF DEPARTMENT OF HAEMATOLOGY OF CHU OF CONSTANTINE IN ALGERIA.

N. Salhi[1,*], M. Benhalilou[1], F. Mezhoud[1], S. kebaili[1], Z. Ouchenane[1]
[1]Haematology, university hospital , Constantine, Algeria

PO212

Association of Von Willebrand Disease Type 2N and Connective Tissue Abnormality Resembling Ehlers-Danlos Syndrome: A Case Report

R. Messaoudi[1,*]
[1]CHU oran and Medecine faculty of Oran, Oran, Algeria

PO213

Accumulation of Factor VIII and von Willebrand Factor during prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate during the WIL-31 Study

V. V. Kateryna[1], V. Vdovin[2], M. A. Timofeeva[3], C. D. Khayat[4], A. Inati[5], R. F. Sidonio Jr[6,*]
[1]National Specialized Children's Hospital Okhmatdyt, Kyiv, Ukraine, [2]Morozovskaya Children's City Clinical Hospital, Moscow, [3]3Federal State Budgetary Scientific Institution "Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal Medical and Biological Agency", Kirov, Russian Federation, [4]Hotel Dieu de France Hospital, Saint Joseph University, Beirut, [5]NINI Hospital and LAU Gilbert and Rose-Marie Chaghoury School of Medicine, Tripoli, Byblos, Lebanon, [6]Department of Pediatrics, Emory University School of Medicine, Atlanta, United States

PO214

Successful desensitization protocol following anaphylaxis secondary to recombinant factor VIIa

A. Mohand Oussaid[1,*], N. boukhedouma[1], L. sekfali[1,1], N. K. benhalla[1], N. Bouterfas[1], F. bouferoua[1]
[1]pediatric, chu beni messous, algiers, Algeria

PO215

ESTABLISHMENT OF DIAGNOSTIC FACILITIES FOR THE AUTOSOMAL RECESSIVE BLEEDING DISORDERS IN PAKISTAN

A. Naz[1,*], H. Patel[2], S. Ahmed[3], T. Masood[4], T. Farzana[3], M. Borhani[5], I. D. Ujjan[1], T. S. Shamsi[3]
[1]Liaquat University of medical and heath sciences, hyderabad, [2]Martin Dow, [3]NIBD, [4]Jinnah medical and dental college, [5]ziaudin medical university, Karachi, Pakistan

PO216

Elevated soluble endoglin could play a role in bleeding by interfering with platelet aggregation and thrombus stability

E. Rossi[1,*], M. Pericacho[2], A. Kauskot[3], L. Gamella-Pozuelo[2,4], E. Reboul[1], A. Leuci[1], C. Egido-Turrion[2], D. El Hamaoui[1], A. Marchelli[1], F. J. Fernandez[4], I. Margaill[1], M.-C. Vega[4], P. Gaussem[1,5], S. Pasquali[6], D. M. Smadja[1,5], C. Bachelot-Loza[1], C. Bernabeu[4]
[1]Innovative Therapies in Hemostasis, INSERM U1140, Universite´ Paris Cite´ , Paris, France, [2]Department of Physiology and Pharmacology, Universidad de Salamanca, Salamanca, Spain, [3]HITh, INSERM UMR-S 1176, Universite´ Paris-Saclay, Le Kremlin-Bicetre, France, [4]Centro de Investigaciones Biologicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain, [5]Service d'hematologie biologique, Hopital Europeen Georges Pompidou, AP-HP, [6]Cibles The´ rapeutiques et Conception de Me´ dicaments (CiTCoM), UMR8038 CNRS, Paris, France

PO217

Clinical presentation and management of Factor XIII deficiency : Case Study

I. Sasmaz[1,2,*], B. Antmen[1], D. A. Tuncel[3], U. Aygunes[1]
[1]Pediatric Hematology, Acibadem Adana Hospital, [2]Pediatric Hematology, Çukurova University, [3]Pediatric Hematology, Adana City Hospital, Adana, Türkiye

PO218

Coagulation factor FXII – is a rare coagulopathy or a common laboratory finding?

I. Iskrov[1], L. Shashok[1], K. Kabayeva[2,*]
[1] Minsk Clinical Consulting and Diagnostic Center, [2]Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus

PO219

Heavy Menstrual Bleeding in An Adolescent with Platelet GP VI Deficiency And Thrombocytopenia: A Challenge Between Hereditary Or Acquired

S. Alavi[1], M. Ahmadinejad[2], N. Shams[1], M. Shahbazi[2], P. Eshghi[1,*]
[1]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran., [2]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., Tehran, Iran, Islamic Republic Of

PO220

Leukocyte Adhesion Deficiency, Type III in An Infant Presenting With Intestinal Obstruction: A case report from Iran

S. Alavi[1,*], N. Shams[2], M. Ahmadinejad[3], F. Malek[1], S. Sharafian[4]
[1]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran., [2]Pediatric Congenital Hematologic Disorders Research Center, Tehran, Iran., [3]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran., [4]Mofid Children Hospital, Pediatric Immunology department, Tehran, Iran, Islamic Republic Of

PO221

Pharmacological management of Paroxysmal Nocturnal Hemoglobinuria in UK: a critical appraisal

Y. M. D. S. Pires[1,*], F. Deffert[1], T. Humenhuk[1], A. P. O. Vilela[2], A. Wiens[1]

[1]Pharmaceutical Sciences, [2]Pharmaceutical Assistance, UFPR, Curitiba, Brazil

PO222

Complex Thrombotic and Hemorrhagic Events in a Patient with Takayasu Arteritis, FVII Deficiency, FV Leiden Thrombophilia, and Multiple Cardiovascular Interventions: A Case Report

A. Movsisyan[1,*], L. Hambardzumyan[1], L. Petrosyan[1], K. Arustamyan[2], V. Hovakimyan[3], C. Stepanyan[3], A. Haroyan[4], M. Movsisyan [5], S. Arakelyan[1], G. Tamamyan [6], N. Sargsyan[1], H. Khachatryan[1]
[1]Hemophilia and Thrombosis Center, Yeolyan Hematology and Oncology Center, [2]Research Center of Maternal and Child Health Protection, [3]Nork-Marash Medical Center, [4]Rheumatology Department, Erebuni Medical Center, [5]Scientific Center of Traumatology and Orthopedics, [6] Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia

PO223

Rare acquired bleeding disorders: a challenge in diagnosis and management.

C. Brito[1,*], M. Oliveira[1], M. Coutinho[1], M. Pereira[1], R. Matos[1], L. Moreira[1], N. Pinho[1], N. Seidi[1], E. Cruz[1], S. Morais[1]
[1]Congenital Coagulopathies Centre & Thrombosis and Hemostasis Unit, Centro Hospitalar Universitário de Santo António, Porto, Portugal

PO224

Factor XI deficiencies and deliveries - an observationnal study in Paris Saclay Hospitals

C. Lavenu-Bombled[1,2,*], M. Billeret[3], A. Blandinieres[2,4], D. Touati[5], R. Garreau[6], C. Desconclois[6], A. Le Gouez[7], M. Bruyere[3]
[1]Inserm UMR 1176, Université Paris Saclay, [2]Service Hématologie Biologique CRC MHEMO, Hôpital Bicêtre, APHP, [3]Service d'Anesthésie - Réanimation Médecine Péri Opératoire, APHP Hôpital Bicêtre, [4]Inserm UMR 1176, Université Paris Saclay,, [5]Service Hématologie Biologique CRC MHEMO, Hôpital Bicêtre, APHP Hôpital Bicêtre, Le Kremlin-Bicêtre, [6]Service Hématologie Biologique, [7]Service d'Anesthésie - Réanimation, APHP Hôpital Béclère, Clamart, France

PO225

Genetic Association of Tissue Factor Pathway Inhibitor (TFPIrs7586970 variant) with Circulating Tissue Factor Pathway Inhibitor Levels and Ischemic Coronary Artery Disease.

D. Abdel Hamid[1,*], N. Wissa[1], N. Abdelalim[1], A. Abdellah[2], M. A. Abdel Hamid[3]
[1]Clinical pathology, [2]Cardiology, [3]Public health, Faculty of medicine, Suez canal university, Ismailia, Egypt

PO226

Assessment of fibrinolytic status in bleeding disorders of unknown etiology

E. G. Arias-Salgado[1,*], A. Leal Ferrero[1], M. T. Alvarez Roman[1,2], E. Monzon Manzano[1], I. Rivas Pollmar[1], E. Garcia Perez[1], M. Martin Salces[1], P. Acuña[1], N. Butta Coll[1], M. Gutierrez Albariño[1], V. Jimenez Yuste[1,2]
[1]Thrombosis and Hemostasis Unit, Hospital Universitario La Paz - IdiPAZ, [2]Medicine Department, Autonomous University of Madrid, Madrid, Spain

PO227

MAGT1 deficiency in XMEN disease is associated with impaired platelet function

E. Monzón Manzano[1,*], L. D. P. Molina[2,3], E. G. Arias-Salgado[1], E. L. Granados[2,3], P. A. Butta[1], C. Gianelli[2,3], J. B. Fernández[2], M. T. Á. Román[1,4], V. J. Yuste[1,4], N. V. B. Coll[1]
[1]Thrombosis and Hemostasis Unit, [2]Clinical Immunology Unit, Hospital Universitario La Paz – IdiPAZ, [3]CIBERER U767, Center for Biomedical Network Research on Rare Diseases , [4]Medicine Department, Autonomous University of Madrid, Madrid, Spain

PO228

Thromboelastometry to evaluate coagulation in Venous Malformations

E. Monzón Manzano[1,*], F. D. B. Nava y Hurtado de Saracho[2], J. C. L. Gutiérrez[2], M. T. Á. Román[1,3], E. G. Arias-Salgado[1], P. A. Butta[1], V. J. Yuste[1,3], N. V. B. Coll[1]
[1]Thrombosis and Hemostasis Unit, Hospital Universitario La Paz – IdiPAZ, [2]Pediatric Surgery Unit, Hospital Universitario La Paz , [3]Medicine Department, Autonomous University of Madrid, Madrid, Spain

PO229

Silent Convergence: Thrombocytopenia and severe Factor X Deficiency Co-Occurrence

E. Hammami[1,*], I. HARZALLAH[2], A. Debliquis[1]
[1]Groupe Hospitalier Mulhouse et Sud Alsace, MULHOUSE, France, [2]Laboratory hematology, Groupe Hospitalier Mulhouse et Sud Alsace, MULHOUSE, France

PO230

Hyperfibrinolysis as an undiagnosed cause of haemorrhage: evaluation of 67 individuals with plasminogen activator inhibitor 1 (PAI1) deficiency

C. Brito[1], E. Cruz[1,*], M. Falavigna[1], I. Damásio[2], F. Dias[1], M. Pereira[1], R. Matos[1], L. Moreira[1], N. Pinho[1], N. Seidi[1], M. Coutinho[1], S. Morais[1]
[1]Congenital Coagulopathies Centre & Thrombosis and Hemostasis Unit, Centro Hospitalar Universitário de Santo António, Porto, [2]Clinical Hematology Unit, Centro Hospitalar de Tondela-Viseu, Viseu, Portugal

PO231

Morbidity in Factor XIII Deficiency

M. Naderi[1,*], I. Mirzaei[2]
[1]Pediatrics Hematology and Oncology, [2]School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran, Islamic Republic Of

PO232

Utility of activated partial thromboplastin time coagulation waveform analysis for patients with acquired hemophilia A

J. A. Rodriguez Alen[1,*], M. J. González Díaz[1], M. D. M. García-Patos García-Patos[1], R. López Torremocha[1], N. Rollón Simón[1], P. Pérez López[1], N. Alba Urdiales[1], N. Espinosa Lara[1], M. D. L. O. Abío Calvete[1], J. Cuesta Tovar[1]
[1]Servicio de Hematología, Hospital Universitario de Toledo, Toledo, Spain

PO233

A NOVEL HOMOZYGOUS VARIANT DISRUPTING SPLICING SITE OF VPS33B CAUSING BLEEDING OF UNKNOWN CAUSE

L. Díaz-Ajenjo[1], A. Marín-Quílez[2], J. Pla-Muñoz[1], B. Rey-Bua[3], P. García-Jaén[3,*], S. Santos-Mínguez[1], C. Miguel-García[1], C. Cabrero-Tejero[1], J. R. González-Porras[3], R. Benito[1], J. Rivera[2] on behalf of Grupo Español de Alteraciones Plaquetarias Congénitas (GEAPC), J. M. Bastida[3] on behalf of Grupo Español de Alteraciones Plaquetarias Congénitas (GEAPC)
[1]Centro de Investigación del Cáncer – CSIC – Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, [2]Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Murcia, [3]Servicio de Hematologia, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain

PO234

Clot waveform analysis for intrinsic pathway factors abnormalities

M. Said[1], W. El Borgi[1], O. Ghali[1], S. Fekih Salem[1], F. Ben Lakhal[1], E. Gouider[1,*]
[1]Biological hematology, Aziza Othmana hospital, Tunis, Tunisia

PO235

Evaluation of the causes of deaths in families with Factor XIII Deficiency

M. Naderi[1,*], I. Mirzaei[2]
[1]Pediatrics Hematology and Oncology, [2]School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran, Islamic Republic Of

PO236

Three case reports of afibrinogenemia: different phenotypes and different clinical evolutions. An open issue

M. Bardetta[1,*], C. Sella[1], C. Dainese[1], F. Valeri[1], R. Romagnoli[2], A. Borchiellini[1], S. Martini[3]
[1]Regional Reference Center for Thrombotic and Hemorrhagic Diseases, Division of Hematology, [2]General Surgery 2U and Liver Transplantation Center, University of Turin, [3]Gastrohepatology Unit, Molinette Hospital, Turin, Italy

PO237

ADAMTS-13 Activity and its Implications in Pediatric Sepsis: A Synthesis of Key Findings from a Decade of Research

M. Hetman[1,*], E. Latos-Grazynska[1]
[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Clinical Hospital, Wroclaw, Poland

PO238

From Severe Sepsis to Amputation: The Pivotal Role of ADAMTS13 Deficiency in Pediatric Outcomes

M. Hetman[1,*], E. Latos-Grazynska[1], A. Kubica-Cielinska[2]
[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, [2]Department of Anesthesiology and Intensive Care for Children, Wroclaw Clinical Hospital, Wroclaw, Poland

PO239

Management of Glanzmann Thrombasthenia: A European Survey On Current Clinical Practice

M. Fiore[1,2,*], R. E. SCHUTGENS[3], M. MATHIAS[4], A. ARTONI[5], R. KLAMROTH[6], R. D'OIRON[7] on behalf of EAHAD Glanzmann Working Group
[1]French Reference Centre for Inherited Platelet Disorders, [2]Department of Haematology, University Hospital of Bordeaux, Pessac, France, [3]Center for Benign Hematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Centre Utrecht, University Utrecht, Utrecht, Netherlands, [4]Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, [5]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [6]Department of Internal Medicine, Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany, [7]Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Constitutionnelles rares, Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, France

PO240

Targeting Tissue Factor Pathway Inhibitor with concizumab to improve haemostasis in patients with Glanzmann thrombasthenia: an in vitro study

J. Dubut[1], V. Goin[2], C. Derray[1], Y. Huguenin[3], M. Fiore[1,2,4,*]
[1]Department of Haematology, [2]French Reference Centre for Inherited Platelet Disorders, [3]Competence Centre for Inherited Bleeding Disorders, University Hospital of Bordeaux, [4]Inserm U1034, Biology of Cardiovascular Disease, University of Bordeaux, Pessac, France

PO241

Prospective Examination of Acquired von Willebrand Syndrome Co-occurrence in Patients with BCR-ABL1-negative Myeloproliferative Neoplasms.

M. H. Aswad[1,2,*], J. Kissova[1,2], T. Ivanicova[1], P. Smejkal[1,2], P. Ovesna[3], A. Bulikova[1,2]

[1]Department of Clinical Hematology, University Hospital Brno, [2]Faculty of Medicine, [3]Institute of Biostatistics and Analyses, Masaryk University , Brno, Czech Republic

PO242

Hemorrhagic PHENOTYPE OF FACTOR VII DE FICIENCY BETWEEN BIOLOGY AND CLINICAL

N. Ferroudj[1,*], M. bensadok[1], M. terchi[1], N. zidani[1], S. M. nekkal[1]
[1]Beni Messous hospital, hematology, Algiers, Algeria

PO243

Assessment Of Bleeding Among Paediatric Patients at a Tertiary Care Centre Unveiled Low Vitamin K Levels

N. Mumtaz[1,*], I. Ujjan[1]
[1]Pathology / Haematology, Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan

PO244

Factor VII deficiency : Monocentric experience

N. Ben Sayed[1,*], T. Belazreg[1], R. Aidli[1], F. Cherif[1], S. Ncibi[1], A. Dhib[1], K. Zahra[1], W. chambeh[1], M. guermazi[1], Y. ben youssef[1], H. Regaieg[1], B. ouni[2], A. Khélif[1]
[1]hematology, [2]parmacology, fahat hached, sousse, Tunisia

PO245

Bleeding disorders in heavy menstrual bleeding; Debunking myths and revealing facts

M. Talaat[1], A. Ayad[1], M. H. Elsaid[2], S. Adolf[3], N. Tawfik Khodir[1,*]
[1]Internal Medicine Department, Clinical Hematology Unit, [2]Obstetrics and Gynecology Department, Faculty of Medicine, Cairo University, Cairo, [3]Hematology, National research centre, Giza, Egypt

PO246

Shedding light on the intersection of rare bleeding disorders and heavy menstrual bleeding

A. Ayad[1], M. Talaat[1], M. H. Elsaid[2], S. Adolf[3], N. Tawfik Khodir[1,*]
[1]Internal Medicine Department, Clinical Hematology Unit, [2]Obstetrics and Gynecology Department, Faculty of Medicine, Cairo University, Cairo, [3]Hematology, National research centre, Giza, Egypt

PO247

A novel heterozygous variant in COL3A1 related to vascular Ehlers-Danlos Syndrome found in study of bleeding of unknown cause

P. García Jaén[1,*], J. M. Navarro García[1], D. Palomino Mendoza[1], P. Bandini[2,3,4], T. Costas Rodríguez[5,6,7], M. D. L. Á. Cabrero Segurado[5], J. R. González Porras[1,8,9], I. Corrales Insa[2,3,10], J. M. Bastida Bermejo[1,8,9]
[1]Hematology and Hemotherapy Department, University Hospital of Salamanca, Salamanca, [2]Medicina Transfusional, Vall d`Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), [3]Laboratori Coagulopaties Congènites, Banc de Sang i Teixits, [4]Departament de Genètica, Microbiologia i Estadística, Universitat de Barcelona, Barcelona, [5]Gynecology and Obstetrics Department, University Hospital of Salamanca, [6]Research group on Gynecology and Obstetrics, University of Salamanca, [7]Human reproduction research group, [8]Institute of Biomedical Research of Salamanca (IBSAL), [9]University of Salamanca, Salamanca, [10]CIBER de Enfermedades Cardiovasculares (CIBERCV), Barcelona, Spain

PO248

Glanzmann Thrombasthenia and total thyroidectomy: a hemostatic challenge

R. Queirós Pereira[1,*], C. Santos[1], D. Carneiro Leão[1], T. Mota[1], M. Lopes[1], S. Fernandes[1], M. D. C. Koch[1]
[1]Centro Hospitalar Universitário de São João, Porto, Portugal

PO249

Screening of inherited bleeding disorders in a large French cohort of women with abnormal uterine bleeding (AUB) : analysis of a « lived » experience

R. Lucia[1,*], G. Gouy[1], M. Cortet[1], G. Dubernard[1], Y. Dargaud[2]
[1]Gynecology, [2]Hemostasis Unit, Hospices Civils de Lyon, Lyon, France

PO250

Gynecological and obstetrical manifestations in women with congenital fibrinogen deficiencies

S. Mohsenian[1,*], R. Palla[1], M. Menegatti[2], F. Peyvandi[1,2] on behalf of the PRO-RBDD study group
[1]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, [2]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy

PO251

Management of an ovarian cyst rupture in an adolescent with Glanzmann's thrombasthenia

S. Ferreira[1,*], F. Rodrigues[2], A. Pereira[2], C. Catarino[2]
[1]Serviço de Imunohemoterapia - Centro Hospitalar Barreiro Montijo, Barreiro, [2]Centro de Referência de Coagulopatias Congénitas - Centro Hospitalar Universitário Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal

PO252

Struma Nodosa Prevalence in European Factor XI Deficiency Patients

S. Halimeh[1,*], M. Siebert[1], R. S. Alesci[2]
[1]Gerinnungszentrum rhein ruhr, Duisburg, [2]Gerinnungszentrum Hochtaunus, Bad Homburg, Germany

PO253

Proteomic screening in Bleeding Disorders of Unknown Cause

T. T. van Duijl[1,*], A. L. Monard[2], C. M. Mussert[3], Y. M. Henskens[4], R. E. Schutgens[5], M. J. Kruip[6], C. van der Zwaan[1], M. H. Cnossen[3], F. C. Heubel-Moenen[2], M. van den Biggelaar[1]
[1]Department of Molecular Hematology, Sanquin Research, Amsterdam, [2]Department of Hematology, Maastricht University Medical Centre, Maastricht, [3]Department of Pediatric Hematology, Erasmus MC Sophia Children's Hospital, Rotterdam, [4]Department of Clinical Chemistry and Laboratory Medicine, Maastricht University Medical Center, Maastricht, [5]Center for Benign Haematology, Thrombosis and Haemostasis, University Medical Center Utrecht and University Utrecht, , Utrecht, [6]Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands

PO254

Evaluation of ADAMTS13 and von Willebrand factor antigen in Covid-19 Patient

W. Iqbal[1,*], K. Aamir[1], A. Naaz[1]
[1]Haematology, Liaquat university of medical and health sciences jamshoro, Hyderabad, Pakistan

PO255

A first genetically proven case of factor VII deficiency in Latvian family

Z. Kovalova[1,2,*], K. Bernate[3], B. Lace[4]
[1]Pediatric , Riga Stradinsh University, [2]Haematology/Oncology, University Children's Hospital, [3]Pauls Stradinsh University Hospital, [4]Rigas East University Hospital, Riga, Latvia

PO256

Characteristics of patients with hereditary combined factor V and factor VIII deficiency in Russia

E. Yakovleva[1,*], O. Pshenichnikova[2], V. Surin [2], N. Sats[3], E. Orel[4], D. Vybornykh[5], N. Zozulya[1]

[1]Department of Hemostasis Disorders, [2] Laboratory of Genetic Engineering, [3] Laboratory of Hematopoietic Physiology, [4] Central Clinical Diagnostic Laboratory, [5]National Medical Research Center for Hematology, Moscow, Russian Federation

PO257

Enhanced thrombin and plasmin generation profiles in alpha-2-antiplasmin deficient patients: Data from the RBiN study

B. Haisma[1,2,*], N. M. Blijlevens[1], M. H. Cnossen[3], P. L. den Exter[4], I. C. Kruis[5], K. Meijer[6], L. Nieuwenhuizen[7], N. van Es[8], R. E. Schutgens[9], S. R. Rijpma[2,10], W. L. van Heerde[2,11], S. E. Schols[1,2]
[1]Department of Hematology, Radboud university medical center, [2]Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, [3]Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, Rotterdam, [4]Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, [5]Netherlands Hemophilia Society, Nijkerk, [6]Department of Hematology, University Medical Center Groningen, Groningen, [7]Department of Hematology, Maxima Medical Center, Eindhoven, [8]Department of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, [9]Department of Benign Hematology, University Medical Center Utrecht, Van Creveldclinic, Utrecht, [10]Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, [11]Enzyre BV, Noviotech Campus, Nijmegen, Netherlands

PO258

Management of Surgical Intervention in a Patient with Congenital Factor XIII Deficiency: A Case Study

N. Kotsiou[1,*], E. Gavriilaki[1], S. Chissan[1], Z. Ntova[1], E. Moka[1], P. Kalmoukos[1], S. Vakalopoulou[1]
[1]Hemophilia Center of Northern Greece, Thessaloniki, Greece

PO259

No added value of testing for factor XIII and α2-antiplasmin deficiency in patients with a mucocutaneous bleeding disorder of unknown cause

S. Ariëns[1,*], A. Huisman[2], I. C. L. Kremer Hovinga[1], R. T. Urbanus[1], K. P. M. van Galen[1], L. F. D. van Vulpen[1], K. Fischer[1], R. E. G. Schutgens[1]
[1]Deparment for Benign Haematology, Thrombosis and Haemostasis, van Creveldkliniek, University Medical Center Utrecht and Utrecht University, [2]Central diagnostic laboratory, University Medical Center Utrecht, Utrecht , Netherlands

PO260

Current practice regarding Bleeding Disorder of Unknown Cause (BDUC) in the Netherlands: a national survey

C. Mussert[1,*], A. Monard[2,3], M. Kruip[4], Y. Henskens[3,5], M. van den Biggelaar [6], T. van Duijl[6], R. Schutgens[7], S. Schols[8], K. Fijnvandraat[9], K. Meijer[10], P. den Exter [11], L. Nieuwenhuizen[12], I. van Moort [4], M. Cnossen[1], F. Heubel-Moenen[2,3] on behalf of for the BDUC-iN study group
[1]Department of pediatric hematology, Erasmus University Medical Center Sophia Children's Hospital, Rotterdam, [2]Department of internal medicine – hematology, [3]CARIM - school for cardiovascular disease, Maastricht University Medical Center, Maastricht, [4]Department of hematology , Erasmus University Medical Center, Rotterdam, [5]Department of Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, [6]Department of molecular hematology, Sanquin Research, Amsterdam, [7]Center for Benign Haematology, Thrombosis and Haemostasis, University Medical Center Utrecht - Van Creveldkliniek, Utrecht, [8]Department of internal medicine – hematology, Radboud University Medical Center, Nijmegen , [9]Department of pediatric hematology, Amsterdam University Medical Center, Amsterdam, [10]Department of internal medicine – hematology, University Medical Center Groningen, Groningen , [11]Department of internal medicine – vascular medicine, Leiden University Medical Center, Leiden, [12]Department of internal medicine – hematology, Maxima Medical Center, Veldhoven, Netherlands

PO261

Experience in the Treatment of ITP with Fostamatinib

P. Pérez García[1], B. D. Roldán[1,*], J. F. D. Rodriguez[1], J. C. D. L. R. García[1], C. G. Barroso[1]

[1]Hematologia, Hospital Juan Ramón Jimenez, Huelva, Spain

PO262

Sexuality and Reproductive Choices in Rare Bleeding Disorders: Data from the RBiN Study

S. P. Willems[1,2,*], J. L. Saes[3], M. Cnossen[4,5], N. van Es[6], P. L. den Exter[7], I. C. Kruis[8], K. Meijer[9], L. nieuwenhuizen[2,10], R. E. Schutgens[11], N. M. Blijlevens[1], W. L. van Heerde[1,12], S. E. Schols[1,2] on behalf of RBiN study group
[1]Department of Hematology, Radboudumc, Nijmegen, [2]Hemophilia Treatment Center, Nijmegen-Eindhoven-Maastricht, [3]Department of Hematology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, [4]Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, [5]University Medical Center Rotterdam, Rotterdam, [6]Department of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, [7]Department of Medicine - Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, [8]Netherlands Hemophilia Society, Nijkerk, [9]Department of Hematology, University Medical Center Groningen, Groningen, [10]Department of Hematology, Máxima Medisch Centrum, Eindhoven, [11]Department of Benign Hematology, van Creveldkliniek, University Medical Center Utrecht, Utrecht, [12]Novio Tech Campus, Enzyre BV, Nijmegen, Netherlands

PO263

Clinical value of laboratory diagnostics for bleeding disorders in general practice

L. Klinkenberg[1], A. Monard[2,3,*], E. Beckers[2,4], A. van der Veer[5], F. Heubel-Moenen[2], Y. Henskens[1,3]
[1]Central Diagnostic Laboratory, [2]Internal Medicine - Hematology, Maastricht University Medical Centre+, [3]CARIM - school for cardiovascular disease, [4]GROW - school for oncology and reproduction, Maastricht University, [5]Pediatrics, Maastricht University Medical Centre+, Maastricht, Netherlands

PO264

Fibrinolysis assessment with tPA-ROTEM in patients with Bleeding Disorders of Unknown Cause (BDUC)

A. Monard[1,2,*], D. Hellenbrand[3], P. Verhezen[4], E. Beckers[1,5], Y. Henskens[2,4], F. Heubel-Moenen[1]
[1]Internal Medicine - Hematology, Maastricht University Medical Centre+, [2]CARIM - School for cardiovascular disease, Maastricht University, [3]Central diagnostic laboratory, Maastricht University Medical Centre, [4]Central diagnostic laboratory, Maastricht University Medical Centre+, [5]GROW - school for oncology and reproduction, Maastricht University, Maastricht, Netherlands

PO265

Evaluation of innovative laboratory tests to predict a thrombotic phenotype in a family with dysfibrinogenemia and a novel FGG mutation

A. Monard[1,2,*], E. Castoldi[2,3], I. de Simone[2,3], P. van der Meijden[2,3], K. Wichapong[2,3], W. van Doorn[4], S. Spada[3], D. Hellenbrand[4], A. Stork[5], H. ten Cate[2,3,6], E. Beckers[1,7], F. Heubel-Moenen[1,2], Y. Henskens[2,4]
[1]Internal medicine - Hematology, Maastricht University Medical Centre+, [2]CARIM - school for cardiovascular disease, [3]Biochemistry, Maastricht University, [4]Central diagnostic laboratory, Maastricht University Medical Centre+, Maastricht, [5]Internal medicine - vascular medicine, St Anna Ziekenhuis, Geldrop, [6]Internal medicine - vascular medicine, Maastricht University Medical Centre+, [7]GROW - school for oncology and reproduction, Maastricht University, Maastricht, Netherlands

PO266

Participation in sports in Dutch children and adults with inherited platelet function disorders is similar to the general population: not afraid to participate.

A. Moor[1,*], E. Huisman[2], L. Hooimeijer[3], E. Rettenbacher[4], P. Brons[5], E. Beckers[6], M. Coppens[4], J. Eikenboom[7], K. Meijer[3], R. Schutgens[8], R. Urbanus[8], G. Jansen[2], I. Kremer Hovinga[8] on behalf of all members of the Trombocytopathy in the Netherlands (TIN) study group and NWO Symphony consortium
[1]van Creveld Clinic, University medical center Utrecht, Utrecht, [2]Erasmus university medical center, rotterdam, [3]University medical center Groningen, Groningen, [4]amsterdam university medical center, Amsterdam, [5]Radboud

university medical center, Nijmegen, [6]Maastricht University medical center, Maastricht, [7]Leiden university medical center, Leiden, [8]University medical center Utrecht, Utrecht, Netherlands

PO267

Thrombin-Mediated Cleavage of Membrane Endoglin: Implications in Endothelial Dysfunction.

D. El Hamaoui[1,*], A. Marchelli[1], S. Gandrille[1,2], E. Reboul[1], A. Stepanian[3], B. Palmier[1], L. Iovine[4], F. Lebrin[5,6], C. Denis[7], C. Bernabeu[8], S. David[1,2], P. Gaussem[1,2], S. Pasquali[9], A. Kauskot[7], E. Rossi[1]
[1]Innovative Therapies in Haemostasis UMR_S1140, Université Paris Cité, [2]Service d'hématologie biologique, Hôpital Européen Georges Pompidou, [3]Service d'hématologie biologique, Hôpital Lariboisière , Paris, France, [4]Department of Biosciences and Nutrition Medicinaren , Karolinska Institutet, Huddinge, Sweden, [5]Department of Internal Medicine, Leiden University Medical Center , Leiden, Netherlands, [6]INSERM U1273, ESPCI Paris-PSL, CNRS UMR8063, Institute Physics for Medicine Paris, [7]HITh, UMR-S 1176, INSERM—Faculty of Medicine, University Paris-Saclay, Paris, France, [8]Consejo Superior de Investigaciones Científicas (CSIC), Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain, [9]UMR8038 CNRS, Cibles Thérapeutiques et Conception de Médicaments CiTCoM , Paris, France

PO268

Impact of semantic interoperability and usability-based optimisations on a Clinical Decision Support (CDS) tool to reduce bleeding risk in patients with bleeding disorders.

E. Roche[1,*], N. O'Connell[2], F. mcGroarty[1], M. Lavin [2], S. Kelly[1]
[1]Informatics , [2]Haematology, St James's Hospital, Dublin , Ireland

PO269

IMPLEMENTATION OF SINGLE FACTOR X REPLACEMENT TREATMENT IN ADULTS WITH INHERITED SEVERE FACTOR X DEFICIENCY

M. Moriarty[1,2], H. V. Maria Buruno[1,3,*], C. Bergin[1], E. Singleton[1], N. Larkin[1], N. O'Connell[1]
[1]National Coagulation Centre, St.James's Hospital, Dublin 8, [2]School of Medicine , Trinity College Dublin, Dublin , [3]School of Medicine, University Hospital Limerick, Limerick, Ireland

PO270

Mutation spectrum of MYH9 gene in Russian population.

J. Poznyakova[1,*], O. Pshenichnikova[1], O. Mishina[1], A. Tolmacheva[2], E. Pustovaya[2], E. Yakovleva[3], A. Melikyan[2], N. Zozulya[4], V. Surin[1]
[1]Laboratory of Genetic Engineering, [2]Department of Standardization of Hematological Treatment Methods, [3]Department of diagnosis and treatment of hematological diseases, [4]Department of Hematology and Hemostatic Disorders, National Medical Research Center for Hematology, Moscow, Russian Federation

PO271

Clinical management of a patient with Bernard-Soulier syndrome misdiagnosed with von Willebrand disease.

J. Poznyakova[1,*], O. Pshenichnikova[1], O. Mishina[1], D. Chernetskaya[1], A. Tolmacheva[2], A. Melikyan[2], E. Likhacheva[3], N. Zozulya[3], V. Surin[1]
[1]Laboratory of Genetic Engineering, [2]Department of Standardization of Hematological Treatment Methods, [3]Department of Hematology and Hemostatic Disorders, National Medical Research Center for Hematology, Moscow, Russian Federation

PO272

Severe anemia and red blood cell transfusions in patients with Rendu-Osler-Weber disease - a retrospective study based on single centre experience

J. Jędras[1,*], J. Zdziarska[1], T. Sacha[1]
[1]University Hospital in Krakow, Krakow, Poland

PO273

Diagnosis of patients with bleeding of unknown cause

P. Acuña[1,*], E. Monzón Manzano[1], E. G. Arias-Salgado[1], E. García Pérez[1], M. T. Álvarez Román[1,2], M. Martín Salces[1], M. I. Rivas Pollmar[1], P. Lopez Gotor[1], V. Jimenez-Yuste[1,2], N. Butta[1]
[1]Thrombosis and Hemostasis Unit, Hospital Universitario La Paz - IdiPAZ, [2]Medicine Department, Autonomous University of Madrid, Madrid, Spain

PO274

Non-Invasive Diagnosis of Anemia Using Conjunctival Photos

R. Çayır[1,*], Y. Durusoy[1], M. N. Yenerel[2]
[1]İstanbul Faculty of Medicine, İstanbul, Türkiye, [2]Internal Medicine, İstanbul Faculty of Medicine, İstanbul, Türkiye

PO275

Constitutional hemorrhagic diseases and surgery, experience in the hematology department bordjbouarreridj .Algeria

S. Lakehal[1,*]
[1]Hematology, EPH Bouzidi Lakhdar, Bordjbouarreridj, Algeria

PO276

Rare Bleeding Disorders in the Obstetric Patients: An Egyptian Center Experience

D. El Demerdash[1], M. T. El Kholy[1,*], A. Ayad[1], S. A. Habib [2] on behalf of Egyptian society of hemophilia, M. Maher[1], T. Abu Zeid[1], I. Zaki[1] on behalf of Egyptian society of hemophilia, Adult hemophilia working group
[1]internal Medicine, kasr alainy school of medicine, Cairo University, [2]pediatric hematology, national research center, Cairo, Egypt

PO277

Inherited FVII deficiency in Egyptian children: A 17 year retrospective study with high incidence of cerebral bleeding

M. Abdelwahab[1,*]
[1]Pediatrics and Pediatric Hematology, Cairo University Pediatric Hospital, Kasr ELainy Hospital, Cairo, Egypt

PO278

Initiatives of the EAHAD Glanzmann Working Group

R. Schutgens[1,*], A. Artoni[2], M. Fiore[3], G. Castaman[4], R. Klamroth[5], M. Mathias[6], W. Miesbach[7], S. Sivapalaratnam[8,9], M. van der Ven[10], R. D'Oiron[11] on behalf of EAHAD Glanzmann Working Group
[1]Center for Benign Haematology, Thrombosis and Haemostasis, van Creveldkliniek, University Medical Center Utrecht and University Utrecht, Utrecht, Netherlands, [2]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy, [3]Laboratoire d'hématologie, Centre de Référence des Pathologies Plaquettaires, , CHU de Bordeaux, Hôpital Cardiologique, Inserm U1034 - Biologie des Maladies Cardio-Vasculaires, Pessac, France, [4]Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy, [5]Department of Internal Medicine Angiology and Coagulation , Vivantes Klinikum im Friedrichshain, Berlin, Germany, [6]Great Ormond Street Hospital for Children NHS Foundation Trust, , London, United Kingdom, [7]Medizinische Klinik 2/Institut für Transfusionsmedizin, , Universitätsklinikum Frankfurt, Frankfurt am Mein, Germany, [8]Department of Haematology, Barts Health NHS Trust, [9]PHURI and Blizard, London, United Kingdom, [10]European Haemophilia Consortium , Brussel, Belgium, [11]Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles, CHU du Kremlin-Bicêtre, Le-Kremlin-Bicêtre, France

PO279

Predictors of Health-Related Quality of Life in Children with Rare Bleeding Disorders at a Single Center

M. Elshinawy[1,*], N. Elshinawy[2]

[1]Faculty of Medicine, Pediatric Hematology, [2]Faculty of Medicine, Alexandria University, Alexandria, Egypt

PO280

Comprehensive Haemophilia care model [CHCM] for haemophilia patients in resource poor settings

S. Pal[1,1,*], T. Roy[1]
[1]oncology, SFCCP, meerut, India

PO281

Alternative system of medicine and joint pain control in hemophilia patients

S. Pal[1,1,*], T. Roy[1]
[1]oncology, SFCCP, meerut, India

PO282

Evaluation/analysis of nurses in hemophilia care: what we need to do ?

S. Rohan[1,*], G. More[1]
[1]community medicine, health alert organisation of india, dhule, India

PO283

When is epistaxis just a nosebleed ? Type 1 von Willebrand Disease diagnosed through a Nurse Led Service.

W. Maposa[1,*], A. Haile[2], C. Brown[1], P. Kanagasabapathy[1], S. Austin[1]
[1]Haemophilia, [2]Coagulation Laboratory, St Georges University Hospitals, London, United Kingdom

PO284

Nursing role as coordinator in a multidisciplinary team in patients with congenital coagulopathy during elective surgeries

A. Eva[1,*], L. Bascuñana [1], C. Fernandez[1], G. Guillen[1], M. Melado[1], N. Soto[1], D. J. Ramos[1], S. D. C. Martinez[1], P. Cabrera[1], V. Sentis[1], O. Benitez[1]
[1]Hemophilia unit, Vall d'hebron Hospital, barcelona, Spain

PO285

The role of the study nurse in congenital coagulation disorders

L. Bascuñana[1,*], E. Alvarez[1], C. Fernandez[1], G. Guillen[1], N. Soto[1], M. Melado[1], D. J. Ramos[1], S. D. C. Martinez[1], P. Cabrera[1], V. Sentis[1], O. Benitez[1]
[1]Vall d'hebron Hospital, barcelona, Spain

PO286

Effectiveness of Myofascial therapy (MFT) and Conventional physiotherapy (CPT) with intermittent prophylaxis on Joint Health in Haemophilic Arthropathy- A Proof of Concept Randomized Control Trial

D. S. Diksha[1,*], M. Makkar[1], M. J. John[1], S. Ojha[1], M. Dhinakaran[2], P. Shukla[3]
[1]Clinical Hematology, [2]Department of Physiotherapy, [3]Department of Global Surgery, Christian Medical College and Hospital, Ludhiana, India

PO287

Developing a novel low-cost orthotic intervention to reduce bleed incidences in haemarthropathy in the global south

H. Talbott[1,*], T. Flannery[2]
[1]University of Hull, Hull, [2]Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

PO288

Posturology in patients with severe Hemophilia A in the province of Salta, Argentina

M. S. CRUZ[1,*], M. D. V. Bertoni[1], J. A. Santillan[1], J. P. G. Ortiz[1], J. N. Castro[1]
[1]Salta, Fundacion de la Hemofilia de Salta, Salta, Argentina

PO289

Physical activity and heavy menstrual bleeding amongst women with inherited bleeding disorders in Ireland.

M. Kennedy[1,*], B. O'Mahony[2], R. Burbridge[2], D. Greene[2], C. Kelly[3,4], M. Lavin[3,4], J. Gormley[1]
[1]Discipline of Physiotherapy, Trinity College Dublin, [2]Irish Haemophilia Society, [3]National Coagulation Centre, St. James's Hospital, [4]Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland

PO290

Comparison of outcome assessment in prophylaxis versus on demand treatment: A research support program of WFH World Bleeding Disorders Registry

D. Viswam[1,*], A. Thomas[1], R. K A[1], V. N. Pillai[1]
[1]Haemophilia, Haemophilia Treatment Centre District Hospital Aluva , Ernakulam, India

PO291

Comparitive study of joint status of hemophilia A severe patients with inhibitor positive and inhibitor negative

J. K Rajan[1,*], D. Viswam[1], A. Ts[1], S. EV[2], S. G. Chiramal[3], V. Narayana pillai[2]
[1]Physiotherapy, [2]Hemophilia, [3]District hospital, Hemophilia treatment centre, District Hospital Aluva, Ernakulam, India

PO292

Development of an evidence-based, expert-driven, practical statement for primary care physiotherapists in the management of persons with bleeding disorders

J. Blokzijl[1,2,*], M. F. Pisters[3,4], C. Veenhof[3,5], R. E. Schutgens[1], M. Aspdahl[6], W. de Boer[7], R. E. Dybvik Matlary [8], D. Douma[9], P. de Kleijn[1], S. Lobet[10,11], P. Loughnane [12], P. McLaughlin[13,14], M. Bladen[15], S. Roche[16], D. Stephensen [17], L. van Vlimmeren [18], L. F. van Vulpen [1], M. Timmer[1] on behalf of On behalf of the EAHAD physiotherapy committee.
[1]Centre for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Centre Utrecht, [2]Physical Therapy Research, Department of Rehabilitation, Physiotherapy Science and Sport, Brain Center Rudolf Magnus, University Medical Center Utrecht, [3]Physical Therapy Research, Department of Rehabilitation, Physiotherapy Science and Sport, Brain Center Rudolf Magnus, University Medical Centre Utrecht, Utrecht, [4]Research Group Empowering Healthy Behaviour, Department of Health Innovations and Technology, Fontys University of Applied Sciences, Eindhoven, [5]Research Group Innovation of Human Movement Care, University of Applied Sciences Utrecht, Utrecht, Netherlands, [6]Women´s Health and Allied Health Professionals Theme. Pediatric occupational therapy and physiotherapy. , Karolinska University Hospital, Stockholm, Sweden, [7]Department of Rehabilitation, Amsterdam UMC, Amsterdam, Netherlands, [8]Department of Clinical Service, Section for physiotherapy and social medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, [9]Centre for rehabilitation, University Medical Centre Groningen, Groningen , Netherlands, [10]Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques Universitaires Saint-Luc, Brussels, [11]Neuromusculoskeletal Lab (NMSK), Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain , Ottignies-Louvain-la-Neuve, Belgium, [12]Children's Health Ireland, Dublin, Ireland, [13]Research Dept of Haematology, University College London, [14]Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, [15]Haemophilia Center, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, [16]National Coagulation Centre, St. James's Hospital, Dublin, Ireland, [17]Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury, United Kingdom, [18]Department of Rehabilitation, Paediatric Physical Therapy, Radboud university medical center, Nijmegen, Netherlands

PO293

The Impact of Musculoskeletal Assessment on Physical Activity Choices and Prophylaxis Decisions: A Case Study of Monozygous Twins with Severe Haemophilia A.

R. Barnard[1,*], P. Raheja[1], P. McLaughlin[2], K. Forsyth[1], D. Stephensen[1,3]
[1]Haemophilia Comprehensive Care Centre, Royal London Hospital, Barts Health NHS Trust, [2]Katherine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, [3]School of Medicine, Health and Social Care, Canterbury Christchurch University, Canterbury, United Kingdom

PO294

Barriers to Home based prophylaxis therapy in Persons with hemophilia (PwH)

A. Dutta[1,2,*], U. S. Gohain[3]
[1]Medicine, Assam Medical College and Hospital, [2]Medicine, HTC, [3]Nursing, Assam Medical College and Hospital, Dibrugarh, India

PO295

A cross-sectional study to estimate socio-economic costs in patients with haemophilia in North-western India

D. S. Diksha[1,*], M. Makkar[2], M. Makkar[1], M. J. John[2], S. Ojha[1]
[1]Clinical Hematology, [2]Clinical Haematology, Christian Medical College and Hospital, Ludhiana, India

PO296

Substance abuse disorder in Hemophilia patients

M. Naderi[1,*], I. Mirzaei[2]
[1]Pediatrics Hematology and Oncology, [2]School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran, Islamic Republic Of

PO297

Study of the quality of life(QoL)of persons with congenital bleeding disease in the cultural space of Estonia

I. Vaide[1,2,*], M. Murd-Rang[2], L. Toplaan[3], I. Jäe[2], L. Hanso[4], C. E. Ursu[5], E. Laane[1,2], H. Everaus[1]
[1]Department of Hemato-Oncology, University of Tartu, Institute of Clinical Medicine, Tartu, [2]Internal Medicin Department, [3]Rehabilitation Department, [4]Department of Psychiatry, Kuressaare Hospital, Kuressaare, Estonia, [5]Onco-Hematology Research Unit, Children Emergency Hospital "Louis Turcanu" Timisoara, Romanian Academy of Medical Sciences, Timisoara, Romania

PO298

Health-related quality of life (HRQoL) in Greek patients with von Willebrand Disease (VWD)

I. Vasilopoulos[1,2], A. Varaklioti[1], A. Kouramba[1,*], V. Aletras[2], E. A. Konstantinou[1], T. Adraktas[1], G. Kanellopoulou[1], O. Katsarou[1]
[1]Blood Transfusion Centre, National Reference Centre for Congenital Bleeding Disorders , Laikon General Hospital, Athens, [2]School of Social Sciences, Hellenic Open University, Patra, Greece

PO299

Physical Activity Awareness Among People with Hemophilia and their Caregivers in Central Europe

A. Batorova[1], A. Banchev[2], A. Boban[3,4], B. Brand[5], M. Brinza[6], B. Faganel-Kotnik[7], C. Kiss[8], G. Puras[9], J. Rajnoch[9,*], E. Zapotocka[10]
[1]Dept. of Hematology and Transfusion Medicine, Faculty of Medicine of Comenius University and University Hospital, Bratislava, Slovakia, [2]Dept. of Pediatric Hematology and Oncology, University Hospital 'Tzaritza Giovanna – ISUL, Sofia, Bulgaria, [3]Dept. of Hematology, University Hospital Center Zagreb, [4]School of Medicine, University of Zagreb, Zagreb, Croatia, [5]Laboratory Division, Kantonsspital Graubünden, Chur, Switzerland, [6]Dept. of Hematology, Fundeni Clinical Institute, Bucharest, Romania, [7]Dept. of Oncology and Hematology, University Children's Hospital, University Medical

Center, Ljubljana, Slovenia, [8]Dept. of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, [9]Sobi, Basel, Switzerland, [10]Dept. of Pediatric Hematology/Oncology, University Hospital Motol, Prague, Czech Republic

PO300

Psychosocial Intervention for Tobacco Addicted People with Hemophilia

M. Hanagavadi[1,*], S. Hanagavadi[2], V. Bhandary[3], R. Annigeri[4]
[1]Karnataka Hemophilia Society Davangere, [2]Pathology, JJM Medical College, Davangere, [3]Psychiatry, Dr A V Baliga Memorial Hospital, Udupi, [4]Oral Medicine & Radiology, College of Dental Sciences, Davangere, India

PO301

Sufferings beyond the Physical impact of Haemophilia- A mixed method study on personal, social, economic domains and its association with quality of life in patients with haemophilia (PWH) and their caregivers (WE CARE)

P. Kharab[1,*], D. Sarwan[1], M. Makkar[1], S. Ojha[1], R. Injety[2], J. John[1]
[1]Department of Clinical Haematology, Haemato- oncology and Bone Marrow (Stem Cell) Transplantation, [2]Department of Neurology, Christian Medical College and Hospital, Ludhiana, India

PO302

Mapping the patient experience in a pediatric hemophilia unit: our patient journey

R. Berrueco[1,*], N. Caballero[1], M. López-Tierling[2], C. Benedicto[1], C. González-Anleo[3], N. Rodríguez-Nieva[4], D. Nadal[2], J. Vinyets[2], M. Jabalera[2]
[1]Pediatric Hematology, [2]Quality and Patient Experience Department, [3]Pharmacy department, [4]Rehabilitation deapartment, Sant Joan de Déu Hospital, Esplugues de Llobregat, Spain

PO303

Phenomenological study on social challenges of mothers with severe haemophiliac children in Iranian culture

F. Feizi[1,2], A. Eshghi[1,2], M. Firoozi[1], Z. Shormeij[2], B. Habib Panah[2], P. Eshghi[2,*]
[1]Department of Psychology, Faculty of Psychology and Education, University of Tehran, [2]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic Of

PO304

Psycho-social support for Haemophilia patients rehabilitation

S. Pal[1,1,*], T. Roy[1]
[1]oncology, SFCCP, meerut, India

PO305

Status report on palliative care in Haemophilia patients : Dark reality in resource poor nations

S. Pal[1,1,*], T. Roy[1]
[1]oncology, SFCCP, meerut, India

PO306

Psychological assessment & QOL improvement project for hemophilia subjects

S. Rohan[1,*], G. More[1]
[1]community medicine, health alert organisation of india, dhule, India

PO307

national hemophilia data registry : Need international consensus

S. Rohan[1,*], G. More[1]
[1]community medicine, health alert organisation of india, dhule, India

PO308

Biofeedback for reducing anxiety associated with injections in people with Haemophilia. A randomized controlled trial

H. Landa[1,*], D. Bashari[1], R. Tiktinsky[1], T. Barazani Brutman[1], G. Kenet[1]
[1]The Israeli National Haemophilia and Thrombosis Institute, Sheba Tel HaShomer Medical Center, Ramat Gan, Israel

PO309

Factors influencing parents'/carers' choice of treatment for their previously untreated child with severe haemophilia A (SHA).

S. E. Pool[1,*], L. Stayt[2,3], K. Rance[3]
[1]Paediatric Haemostasis Unit, [2]Research, Oxford University Hospitals NHS Foundation Trust, [3]Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, United Kingdom

PO310

A New Tool to Assist in Treatment Selection – The World Federation of Hemophilia (WFH) Shared Decision-Making (SDM) Tool

D. Coffin[1,*], J. Chadwick[1], G. Kaeser[2], M. Naccache[1], B. Hayes[3], T. Sannie[4], M. Skinner[5], C. Thornburg[6], G. Pierce[1]
[1]WFH, Montreal, Canada, [2]Independent Consultant, [3]NBDF, USA, United States, [4]Association française des hémophiles , paris, France, [5]Institute for Policy Advancement, Ltd., , Washington, [6]Hemophilia Treatment Center, San Diego, United States

PO311

Biopsychosocial challenges of an Iranian family with a child with co-occurring haemophilia and autism spectrum disorder: A phenomenological case study

A. Eshghi[1,2], F. Maleki[1,2], M. Firoozi[1], B. Habib Panah[2], P. Eshghi[2,*]
[1]Department of Psychology, Faculty of Psychology and Education, University of Tehran, [2]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic Of

PO312

Intergenerational Impact of the Contaminated Blood Scandal

S.-A. Wherry[1,*], L. Berragan[1], R. Jennings[1] on behalf of Women's Working Group
[1]Health, University of Gloucestershire, Gloucester, United Kingdom

PO313

Sexual functioning amongst men with haemophilia in the Netherlands: data from the Haemophilia in the Netherlands-6 study

T. C. M. Van Gastel[1,2,3,*], L. Teela[1,2,4], E. P. Mauser-Bunschoten[5], M. Coppens[6], M. Peters[7], K. Fijnvandraat[7], L. Haverman[1,2,4], S. C. Gouw[7]
[1]Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, [2]Amsterdam Reproduction and Development, Child development, [3]Amsterdam Public Health, Mental Health and Health Behaviors & Chronic Diseases, [4]Amsterdam Public Health, Mental health and Digital health, Amsterdam, [5]University Medical Center Utrecht, Center for Benign Haematology Thrombosis and Haemostasis Van Creveldklinie, Utrecht, [6]Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, [7]Paediatric Haemotology, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, Amsterdam, Netherlands

PO314

Treatment Preferences in People with Severe Haemophilia A: a Discrete Choice Experiment in the United States

W. Miesbah[1,*], L. Valentino[2], B. O'Mahony[3], K. Forsyth[4], M. Bullinger[5], J. M. Gonzalez Sepulveda[6], E. Dashiell-Aje[7], S. Santos[8], H. Lewis[9], D. Latibeaudiere-Gardner[9], T. Tervonen[10], M. Karimi[8]
[1]Department of Haemostasis/Haemophilia Centre/Laboratory for Coagulation Disorders, University Hospital Frankfurt - Institute of Transfusion Medicine & Immunohaematology, Frankfurt, Germany, [2]National Bleeding Disorders Foundation, New York, United States, [3]Irish Haemophilia Society, Dublin, Ireland, [4]Haemophilia Comprehense Care Centre, The Royal London Hospital, London, United Kingdom, [5]Independant, Hamburg, Germany, [6]Department of Population Health Sciences, Duke University School of Medicine, Durham, [7]Biomarin Pharmaceutical Inc., San Raphael, United States, [8]Biomarin Pharmaceutical Inc., London, [9]Patient Centred Outcomes, ICON plc, Reading, United Kingdom, [10]Kielo Research, Zug, Switzerland

PO315

The Dutch version of the PROMIS® Sexual Function and Satisfaction Measures for individuals with haemophilia

T. C. M. Van Gastel[1,2,3,*], L. Teela[1,2,4], V. Lehmann[5], M. Peters[6], C. B. Terwee[7], K. Fijnvandraat[6], L. Haverman[1,2,4]
[1]Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, [2]Amsterdam Reproduction and Development, Child development, [3]Amsterdam Public Health, Mental Health and Health Behaviors & Chronic Diseases, [4]Amsterdam Public Health, Mental health and Digital health, [5]Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, [6]Paediatric Haemotology, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, [7]Department of Epidemiology and Data Science, Amsterdam UMC location University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, Netherlands